dx y tx de icc

IN THIS ISSUE

Produced by

2005 EMCREG-International

www.emcreg.org

Produced by

EM

ER

GE

NC

Y D

IAG

NO

SIS AN

D T

RE

AT

ME

NT

OF

AC

UT

E D

EC

OM

PE

NSA

TE

D H

EA

RT

FA

ILU

RE

(AD

HF

) - MA

RC

H 2005

E

MC

RE

G-International

P r inted in the USA

This educational monograph was supported in part by

an unrestricted educational grant from Scios.

EMERGENCY DIAGNOSIS AND TREATMENT OF

ACUTE DECOMPENSATEDHEART FAILURE (ADHF)

EMERGENCY DIAGNOSIS AND TREATMENT OF

ACUTE DECOMPENSATEDHEART FAILURE (ADHF)

CME Monographfrom the ACEP 2005Spring Congress Satellite Symposium

Orlando, FloridaMarch 4, 2005

CME Monographfrom the ACEP 2005Spring Congress Satellite Symposium

Orlando, FloridaMarch 4, 2005

}>vi

*x-}}i

->ii-

">`]`>>V{]x

) N T E RNA T I ONA L

W W W E M C R E G O R G

%DITEDBY!NDRA,"LOMKALNS-$

!SSISTANT0ROFESSOR2ESIDENCY$IRECTOR$EPARTMENTOF%MERGENCY-EDICINE

5NIVERSITYOF#INCINNATI#INCINNATI/(53!

$IRECTOR#-%AND%NDURING-ATERIALS%-#2%')NTERNATIONAL

7"RIAN'IBLER-$0ROFESSOR#HAIRMAN

$EPARTMENTOF%MERGENCY-EDICINE5NIVERSITYOF#INCINNATI#INCINNATI/(53!

0RESIDENT%-#2%')NTERNATIONAL

*`Vi`L

,i>>

Qi}iVi`Vi>`>V,ii>V>``V>R

*`Vi`L

,i>>

Qi}iVi`Vi>`>V,ii>V>``V>R

%-%2'%.#9$)!'./3)3!.$

42%!4-%.4/&!#54%$%#/-0%.3!4%$

(%!24&!),52%!$(&

%-%2'%.#9$)!'./3)3!.$

42%!4-%.4/&!#54%$%#/-0%.3!4%$

(%!24&!),52%!$(&

>x

i>i>}i\

>Vi>]i>i>ii1i`->i>i>i`>ViìVi>iì>v>ii>]ii>iLiii`>VVi}ìiviii}iV>>}iivV`>>vi,iViiVi>iì>>i >>,i}]`V>i>>i>iii>i`>i`]>ìi>i>i}>ivL`>`>/i>>}ii>`V>iv>i}i>L>/Viii>`}ii}>iii>i` >}V>ì>iV`>iv>`}}iiìiV>ivii>i>}>ìv,>Liiii`>``Vi`

/ii}iVi`Vi>`>V,ii>V>``V>i>>,i>iìii`V>>}> >} x , - i i}iV i>i >} >` /i>i v i` ">`] `> / }> > >>>Li > > ì>ìL V> i Vì` ,">` >\>`v`}VVLi}}ixi>>i>ìii}iVV>v>iVi>i>`v>V>iV>ivi>i>

,`V>>/i v ,i>> ì `>i] iìVi L>i`] >` VV> iv i`V>>>i> i>V>iìiìV>ivii}iVV`7i>i}i>ì>ìvvìii>i>viivViV>L>7iiii`V>>iì>>ii`>L`]i>iVLyiViL>V>iviii`>`VLiìi}>`}>vi`V>>>i>V>Liivii`ìV`>>]]iVv>``}>i>>JiVi}}

-Vii]

VVi`>\/i1ivV>i}ivi`Viì}>ii`V>>>Vv>>vv>i}Vi`>ì*V>,iV}>`>VV>`V>i>ii>V>iii`V>>>V/i1ivV>>VViì`LiVVi`>Vv}i`V>`V>

V}i`V>i`V>vV>

/i`V>>}>>i`>L>iViì`V>>}>v-V

/`ViLii`>>>>`VV>iviiVi>` "/>>Livi>`}i>>Li>`}>Vi`Vi

,Li>Li>iiiv>ìV>ì>V>i>iLi>Viii>i>/`Viìi>Vi``>V>VV>`}i

V>`}i}ìi>Vvi>i}}iLiiwvi>i>}>ivVi]`V>>ì`viv`Vivii`}>>iiVi>i>i>`V>iì>V>}ii>`>Liìi`vivi>i>iiVV>ViViiiVL}v>Livi>ì}

`>>] 7>Li] >*vi],iìViV *vi>`>> i>ivi}iVi`Vi i>ivi}iVi`Vi 1ivV> 1ivV> V>]" V>]" iV]>``}>i> *iì],i>> ,i>>

) N T E RNA T I ONA L

I

II

/>Livi

>}vViiVi>iì>>ii ``>ì]*vii>ivi}iVi`Vi1iv*i>>]*>ì>]*

/i>ivViiVi>iì>>ii x}>>]>*vivi}iVi`Vi7>}1i]-]"

/i},iv *i>}>`/i>iv\->vi *i*>i,i 7>*i>VV]*vi6Vi>],ii>V]i>ivi}iVi`Vi/iii>`V]ii>`]"

>V}`>``}i, /" ,-/,9 7>/L>>]*vi

iv]v>`>V>i`Vi/i"->i1i]L]"

i>i>>}iivViiVi>iì>>i\/i,

i}iVi`Viì ,V>`-i]*vii>ivi}iVi`Vi1ivi`V>ii]>V]-

ViiVi>iì>>ii>i>>}ii/ -i>*]>*vii>ivi}iVi`Vi1ivV>]V>]"

}i`V>`V>+i {

L}

,iLi

7>Li]]*iì1ivV>

V>]"

6>>>>]-}>iii>>-}>i

/*vìiì]i`V>i}iv7V>ii]7V

,Li>>]*>`>V>,ì>i]>

`>>]1ivV>

V>]"

i>`8}>] -i1i>*>i] i9

>`]>>Viii>>]>>Vi

}>>]7>}1i-Vvi`Vi-]

>ii]-*>>6>Vi]L>

-i>*]1ivV>

V>]"

i>i]1i>>Li}ii]i}

iL>-iV]1>i`V>ii->V>i]>v>

i}i>]1ivV>

V>]"

>Vii]

>}ii`V>ii

>>}>]/iiii

ii>i]

>>i`V>ii

>i] >>

>ii]i`V>>i]>>`

>]1ivV>

V>]"

>i7i>]7>ii1i7->i] >>

``>ì]1iv*i>>*>ì>]*i>>

>,`]1ivLi>>

`]Li>]>>`>

-}]i1i/]>>

`>`>V]1ivV>

V>]"

,>`>V]7>i>>,>">]V}>

}>]1>i`V>ii->V>i]>v>

iì]*1ivV>

V>]"

>ì>]*>`>V>,ì>i]>

,V>` >]i`>i]V}>

>>"L>]>>>>>

>" i]->>i]V}>

i*">]i`V>i}iv6}>,V`]6}>

*>V]1ivV>

V>]"

7>*i>VV]/iii>`V

ii>`]"

>i6*>V]1iv*i>>>*>ì>]*i>>

>-ii>Vi]i1ii`V>ii>] >>

7>i-V>`}]9>9]*i>>

i-]6>ìL1i >i]/iiii

,V>`-i]1iv>V]

>,/vv>]>V>i`V>ii*i]>

>i7iLi]1ivV}>]V}>

,Lii]7>i->i1ii]V}>

7>/L>>]*vi

iv]v>`>V>i`Vi/i"->i1i

L]"

}>>]>*vi7>}1i-]

-i>*]>*vi1ivV>

V>]"

``>ì]*vi1iv*i>>*>ì>]*i>>

7>*i>VV]*vi/iii>`V

ii>`]"

,V>`-i]*vi1iv>V]

III

/ii>i}i

v>Vii>v>i

>iv>V>>`

`LiL>`

``i`

V>i}i\i

`i}i}v

ii>v>i]>`

ii}vi

>ViiV>>

ii}

viVV

Vi>i`>i

"--"1/"* -/,/1, /

/,"1/" !SWEHAVEIMPROVEDTHECAREOFPATIENTSWITHACUTECORONARYSYNDROMES!#3PATIENTSWITHCARDIOVASCULARDISEASEARELIVINGLONGERTHANEVER%FFECTIVEINTERVENTIONSTODECREASEMORTALITYOFPATIENTSWITH!#3HAVEINCREASEDTHEINCIDENCEOFHEARTFAILURE4HECOSTOFHEARTFAILURENOWEXCEEDSBILLIONAYEARMOSTOFWHICHISDUETOHOSPITALIZATION5NFORTUNATELYHEARTFAILUREISACHRONICCONDITIONANDNEARLYHALFOFPATIENTSADMITTEDTOTHEHOSPITALAREREADMITTEDWITHINSIXMONTHS4ODETERMINEOPTIMALTHERAPYFORPATIENTSWITHACUTEDECOMPENSATEDHEARTFAILURE!$(&THEEMERGENCYPHYSICIANMUSTBEABLETOCONlDENTLYDIAGNOSEPATIENTSWITHHEARTFAILURE4HISREQUIRESKNOWLEDGEOFTHEDIAGNOSTICMETHODSUSEDTOIDENTIFYPATIENTSWITHHEARTFAILUREASWELLASKNOWLEDGEOFTHEDIFFERENTETIOLOGIESOFHEARTFAILURE

3ORTING/UTTHE%TIOLOGYOF(EART&AILURE4HE POTENTIAL ETIOLOGIES OF ACUTE HEARTFAILURE ARE MULTIFACTORIAL AND SHOULDBE BROADLY DIVIDED INTO TWO CATEGORIES THE UNDERLYING ETIOLOGY OF THE HEARTFAILUREANDTHEETIOLOGYOFTHEACUTEPRECIPITANTTHATRESULTSINWORSENINGFROMTHECHRONICCOMPENSATEDSTATE&ORSOMEPATIENTSPARTICULARLYTHOSEPRESENTINGFORTHElRSTTIMETHESETWOCOMPONENTSMAYBE IDENTICAL 4HE MOST COMMON ETIOLOGIESOFHEART FAILURE ARE CORONARY ARTERYDISEASE AND LONGSTANDINGHYPERTENSION/THER POTENTIAL ETIOLOGIES INCLUDE DILATED HYPERTROPHIC AND RESTRICTIVE CARDIOMYOPATHIES MYOCARDITIS PERICARDIALTAMPONADE VALVULAR HEART DISEASE ANDSECONDARYEFFECTSOFPULMONARYDISEASESORMETABOLICDISORDERS

*UDD%(OLLANDER-$$EPARTMENTOF%MERGENCY-EDICINE5NIVERSITYOF0ENNSYLVANIA

0HILADELPHIA0!

"/6-\ iwiiiv *`}i>v>ivii}iviv

Li> ii>iiiv *v>v}>ii>v>i

!LTHOUGHINVESTIGATIONOFTHEUNDERLYINGETIOLOGY IS IMPORTANT TO HELP DETERMINEWHETHERTHEREISAREVERSIBLECOMPONENTOFTHEDISEASETHISISUSUALLYBEYONDTHESCOPEOFTHEEMERGENCYPHYSICIAN4HEREAREHOWEVERSEVERALETIOLOGIESFORHEARTFAILURE THAT THE EMERGENCY PHYSICIANSHOULDBEAWAREOFASTHEYMAYREQUIREMODIlCATIONOFINITIALTHERAPY4HESEARESEVERE AORTIC STENOSIS IDIOPATHIC HYPERTROPHICSUBAORTICSTENOSISORHYPERTROPHICOBSTRUCTIVECARDIOMYOPATHYANDPULMONARY HYPERTENSION )DENTIlCATION OF PATIENTSWITHTHESECONDITIONSISIMPORTANTBECAUSEAGGRESSIVEPRELOADANDAFTERLOADREDUCTIONCANLEADTOCARDIOVASCULARCOLLAPSESINCETHESEPATIENTSCANNOTINCREASETHEIR FORWARD BLOOD mOW THROUGH THElXEDMECHANICALLESIONSUCHASAmOWRESTRICTEDAORTICVALVE

%MERGENCY$IAGNOSISAND4REATMENTOF!CUTE$ECOMPENSATED(EART&AILURE!$(&

3EPARATEANDDISTINCTFROMTHEINITIALETIOLOGY IS THE CAUSE OF THE ACUTE PRECIPITANT#ONGESTIVEHEARTFAILURECANBEEXACERBATEDBYWORSENINGOFTHEUNDERLYINGCONDITIONBYMEDICATIONORDIETARYNONCOMPLIANCE OR BY DEVELOPMENT OF NEWORCOMPLICATINGMEDICALCONDITIONSEGISCHEMIADYSRHYTHMIASPULMONARYEMBOLUSORINFECTION!PPROXIMATELYOF PATIENTS PRESENTING TO THE EMERGENCYDEPARTMENT%$WITHHEARTFAILUREHAVEAPRIORDIAGNOSISOFHEARTFAILURE

0ROGRESSINTHE$IAGNOSISOF(EART&AILURE4HE DIAGNOSIS OF HEART FAILURE HAS TRADITIONALLYBEENCHALLENGING2ELIANCEUPONCLINICAL IMPRESSION ALONE LEADS TO DIAGNOSTICUNCERTAINTYBECAUSE THE SIGNS ANDSYMPTOMS OF HEART FAILURE ARE RELATIVELYNONSPECIlC+EYSYMPTOMSSUCHASSHORTNESSOFBREATHARENONSPECIlCINPATIENTSWITH COMORBIDITIES SUCH AS REACTIVE AIRWAYDISEASE,IKEWISEROUTINELABORATORYTESTSELECTROCARDIOGRAMSANDRADIOGRAPHSCANNOTBERELIEDUPONTOALWAYSGUIDEANACCURATEANDAPPROPRIATEDIAGNOSIS

$ESPITE THESECHALLENGESDIAGNOSTICCAPABILITIESINHEARTFAILUREHAVEIMPROVEDIN RECENT YEARS WITH RECOGNITION OF THEROLETHAT"TYPENATRIURETICPEPTIDE".0PLAYSINTHEDISEASE)NADDITIONTOBEINGAPUMPTHEHEART ISANENDOCRINEORGANTHATFUNCTIONSTOGETHERWITHOTHERPHYSIOLOGICALSYSTEMSTOCONTROLmUIDVOLUME4HE MYOCARDIUM PRODUCES NATRIURETICPEPTIDESONEOFWHICHIS".0AHORMONEWITH DIURETIC NATRIURETIC AND VASCULARSMOOTHMUSCLERELAXINGACTIONS".0ISANATURAL ANTAGONIST FOR THE SYMPATHETICNERVOUS SYSTEM AND THE RENINANGIOTENSINALDOSTERONEAXIS".0ISSECRETED IN

RESPONSE TOWALL STRETCH VENTRICULAR DILATIONANDOR INCREASEDlLLINGPRESSURES-EASUREMENTOFENDOGENOUS".0ISTHUSACLINICALLYSENSIBLEWAYTOASSESSWHETHERAPARTICULARPATIENTHASHEARTFAILURE

4HE "REATHING .OT 0ROPERLY STUDY OFPATIENTSWHOPRESENTEDTO%$SWITHSHORTNESSOFBREATHSHOWEDTHAT".0LEVELSALONEWEREMOREACCURATEPREDICTORSOFTHEPRESENCEORABSENCEOFHEARTFAILURETHANANYHISTORICALFACTORSPHYSICALlNDINGSOR LABORATORYVALUES".0LEVELSWEREMUCHHIGHER INPATIENTSWHOWERESUBSEQUENTLY DIAGNOSED WITH HEART FAILURETHANINTHOSEDIAGNOSEDWITHNONCARDIACDYSPNEAPGD,VSPGD,!".0 CUTOFF VALUE OF PGM, HADASENSITIVITYOFANDASPECIlCITYOFFORDIFFERENTIATINGHEARTFAILUREFROMOTHERCAUSESOFDYSPNEAANDACUTOFFOFPGM,HADANEGATIVEPREDICTIVEVALUEOF7ITHOUTKNOWLEDGEOF".0LEVELSEMERGENCYPHYSICIANSHADAINDECISIONRATEINTRYINGTOMAKEADIAGNOSIS".0LEVELSADDEDSIGNIlCANTLY TOTHE CLINICAL IMPRESSION AS ITWAS FOUNDTHATCLINICALDECISIONMAKINGINCONJUNCTIONWITH".0LEVELSCOULDHAVEREDUCEDTHEDIAGNOSTICINDECISIONRATETO)NMULTIVARIATEANALYSES".0LEVELSALWAYSCONTRIBUTED TO THE DIAGNOSIS EVEN AFTERTAKING INTO ACCOUNT lNDINGS FROM THEHISTORYANDPHYSICALEXAMINATION4HUSTHE"REATHING.OT0ROPERLYTRIALDEMONSTRATED THAT".0 LEVELS HAVE SIGNIlCANTCLINICAL UTILITY FOR BOTH THE DIAGNOSISAND RISK STRATIlCATION OF HEART FAILUREPATIENTS IN THE%$"OTHDIASTOLICANDSYSTOLICDYSFUNCTIONARE ASSOCIATEDWITHHIGH".0LEVELSOFMOREORLESSTHESAMEDEGREE

,i>ViVV>

i>i

i>``>}V

Vi>LiV>ii

}>`

vi>v>i>i

i>iiVwV

qqqqqqq

/ii>}

*i/>

`i>i`>

*ivv

i`>}v

i

"--"1/"* -/,/1, /

".0MUSTBEUSEDWITHCAUTIONINCERTAINPOPULATIONS!LTHOUGH".0CANHELPDIFFERENTIATEPULMONARYFROMCARDIACETIOLOGIESOFDYSPNEASOMETYPESOF LUNGDISEASE SUCHAS CORPULMONALE ANDPULMONARYEMBOLISMHAVEELEVATED".0LEVELSHOWEVER".0ISNOTUSUALLYELEVATEDASTOASHIGHALEVELASITISINPATIENTSWITHHEARTFAILURE )N A SUBGROUP OF PATIENTSWITH AHISTORY OF REACTIVE AIRWAY DISEASE IN THE"REATHING.OT0ROPERLYTRIALOFSUBJECTSWITHAHISTORYOFASTHMAORCHRONICOBSTRUCTIVE PULMONARY DISEASEWITHOUT AHISTORYOF#(&WEREFOUNDTOHAVENEWLY DISCOVERED #(&/NLY WEREIDENTIlED IN THE%$WHILE A".0PGM,IDENTIlED!DDITIONALLY".0LEVELS PGM, PROVIDED DIAGNOSTICINFORMATIONBEYONDTHATOBTAINEDFROMINDIVIDUALCHESTRADIOGRAPHICINDICATORS

4HERE IS A SIGNIlCANT INVERSE RELATIONSHIPBETWEEN BODY WEIGHT BODY MASS INDEXAND".0 LEVELS4HINPATIENTSWITHHEARTFAILUREAREMORELIKELYTOHAVEELEVATED".0VALUESINTHEABSENCEOFHEARTFAILURE#ONVERSELY OBESE PATIENTS AREMORE LIKELY TOHAVELOWERLEVELSOF".0FORANYGIVENSEVERITYOFHEARTFAILURE!SARESULT".0LEVELSSHOULDBEUSEDWITHCAUTIONINPATIENTSWITHOBESITYUNLESSOFCOURSEBASELINE".0VALUES AREKNOWN4HEN THEOBESEPATIENTCANBEFOLLOWEDFORDECOMPENSATION

4HE "REATHING .OT 0ROPERLY 4RIAL DEMONSTRATEDTHAT".0ISUSEFULFORTHEDIAGNOSIS OF#(& IN THE%$4HE2%$(/43TUDY SUGGESTS THAT ".0 MIGHT ALSO BEUSEFULTOIMPROVETRIAGEANDDISPOSITIONOFPATIENTSWHOPRESENTTOTHE%$WITHHEARTFAILURE4HISTRIALDEMONSTRATEDAhDISCONNECTvBETWEENTHEPHYSICIANPERCEPTIONOFTHESEVERITYOFHEARTFAILUREANDTHEACTUAL".0VALUE)NTHElRSTPHASEPATIENTS

VISITING %$S WITH COMPLAINTS OF BREATHING DIFlCULTY HAD ".0 MEASUREMENTSTAKENONARRIVAL0HYSICIANSWEREBLINDEDTO".0RESULTSHOWEVERINCLUSIONINTHETRIALREQUIREDA".0PGML0ATIENTSDISCHARGEDFROMTHE%$HADHIGHER".0LEVELSTHANTHOSEADMITTEDTOTHEHOSPITALPGMLVSPGML7ITHRESPECTTOTHEADMITTEDPATIENTSHAD".0LEVELSPGMLWHICHISINDICATIVEOFLESSSEVERE#(&-OSTOF THESEPATIENTSWEREPERCEIVEDTOHAVECLASS)))OR)6HEARTFAILURE-ORTALITYFORTHESEPATIENTSWASATDAYSANDONLYATDAYSSUGGESTINGTHATPATIENTSWITHHEARTFAILUREANDLOWLEVELSOF".0MIGHTHAVEACTUALLYBEENSAFEFORDISCHARGE7ITHRESPECTTOPATIENTSTHATWERE ACTUALLY DISCHARGED HAD".0LEVELSPGM,!TDAYSMORTALITYWAS4HEREWASNOMORTALITYOFTHOSEDISCHARGEDWITH".0LEVELSPGM,4HISSUGGESTS THATUSEOF".0INTHE%$MIGHTALSOHELPDETERMINEWHICHWELLAPPEARINGPATIENTSAREHIGHRISKFORABADOUTCOMEOVERTHESHORTTERMDAYS

%LEVATED ".0 LEVELS ARE USEFUL FOR ASSESSING RISK STRATIlCATION AND PROGNOSISINPATIENTSWITHHEARTFAILURE".0LEVELSARE RELATED TO CHANGES IN LIMITATIONS OFPHYSICAL ACTIVITIES AND FUNCTIONAL STATUS(ARRISONETALFOLLOWEDPATIENTSFORMONTHSAFTERANINDEXVISITTOTHE%$FORDYSPNEA(IGHER".0 LEVELSWERE ASSOCIATED WITH A PROGRESSIVELY WORSE PROGNOSIS4HE RELATIVE RISKOFMONTH#(&ADMISSIONORDEATHINPATIENTSWITH".0LEVELSPGM,WASTIMESTHERISKOFPATIENTSWITHLEVELSLESSTHAN7HENCOMBINEDWITHTROPONIN)BOTHTROPONIN)AND".0ALONEANDINCOMBINATIONPREDICTSURVIVALIN#(&"OTHTOGETHERHAVEADDITIVEPROGNOSTICRISK

i>v *>i

ivv>i}

>wV>>`

}>i

i>v>i

4HEUTILITYOF".0 TODIAGNOSIS#(& ISWELL ESTABLISHEDHOWEVERITSABILITYTODRIVETREATMENTISSTILLUNDERSTUDY2%$(/4))ISARANDOMIZEDCONTROLLEDTRIAL COMPARING TREATMENT AND OUTCOMES OF PATIENTSWHERETHERAPYISGUIDEDBYSERIAL".0MEASUREMENTSIN THE EXPERIMENTAL GROUP 4HIS STUDY SHOULD SHEDSOMELIGHTONTHEUTILITYOF".0TODRIVETREATMENT

$UETOTHEVOLUMINOUSDATAONTHECLINICALUTILITYOF".0CONSENSUSPANELGUIDELINESWERERECENTLYPUBLISHED4HESERECOMMENDATIONSSTATE

% -ANYPATIENTSPRESENTINGTOEMERGENCYSERVICESWITH DYSPNEA A HISTORY PHYSICAL EXAMINATIONANDACHESTXRAYAND%#'SHOULDBEUNDERTAKENTOGETHER WITH LABORATORY MEASUREMENTS THATINCLUDE".0

% !S".0LEVELSRISEWITHAGEANDAREAFFECTEDBYGENDERCOMORBIDITYANDDRUGTHERAPYTHEPLASMA".0MEASUREMENTSHOULDNOTBEUSEDINISOLATIONFROMTHECLINICALCONTEXT

% )F THE".0ISPGM, THENHEART FAILURE ISHIGHLYUNLIKELYNEGATIVEPREDICTIVEVALUE

% )F THE ".0 LEVEL IS PGM, THEN #(& ISHIGHLYLIKELYPOSITIVEPREDICTIVEVALUE

% &OR".0LEVELSOFnONESHOULDCONSIDERTHE FOLLOWING CONDITIONS IN THE DIFFERENTIALDIAGNOSISA "ASELINE".0VALUEDUETOSTABLEUNDERLYINGDYSFUNCTION

B 2IGHTVENTRICULARFAILUREFROMCORPULMONALE

C !CUTEPULMONARYEMBOLISMD 2ENALFAILURE

s 0ATIENTSMAYPRESENTWITH#(&WITHNORMAL".0 LEVELS OR WITH LEVELS BELOW WHATMIGHTONEEXPECTCANOCCURINTHEFOLLOWINGSITUATIONSA &LASHPULMONARYEDEMAnHOURSB (EART FAILURE UPSTREAM FROM THE LEFTVENTRICLE IE ACUTEMITRAL REGURGITATIONFROMPAPILLARYMUSCLERUPTURE

C /BESE PATIENTS BODY MASS INDEX KGM

,,

- -AISEL!3+RISHNASWAMY0.OWAK2-ETAL2APID

MEASUREMENTOF"TYPENATRIURETICPEPTIDEINTHEEMERGENCYDIAGNOSISOFHEARTFAILURE.%NGL*-ED

-C#ULLOUGH0!.OWAK2--C#ORD*ETAL"TYPENATRIURETICPEPTIDEANDCLINICALJUDGMENTINEMERGENCYDIAGNOSISOFHEARTFAILUREANALYSISFROM"REATHING.OT0ROPERLY".0-ULTINATIONAL3TUDY#IRCULATION

-AISEL!3-C#ORD*.OWAK2-(OLLANDER*%7U!("$UC0/MLAND43TORROW!"+RISHNASWAMY0!BRAHAM74#LOPTON03TEG0'!UMONT-#7ESTHEIM!+NUDSEN#70EREZ!+AMIN2+AZANEGRA2(ERRMANN(#-C#ULLOUGH0!FORTHE".0-ULTINATIONAL3TUDY)NVESTIGATORS"EDSIDE"TYPENATRIURETICPEPTIDEINTHEEMERGENCYDIAGNOSISOFHEARTFAILUREWITHREDUCEDORPRESERVEDEJECTIONFRACTION2ESULTSFROMTHE"REATHING.OT0ROPERLY".0-ULTINATIONAL3TUDY*!M#OLL#ARDIOL

-C#ULLOUGH0!(OLLANDER*%.OWAK2-ETAL5NCOVERINGHEARTFAILUREINPATIENTSWITHAHISTORYOFPULMONARYDISEASERATIONALEFORTHEEARLYUSEOF"TYPENATRIURETICPEPTIDEINTHEEMERGENCYDEPARTMENT!CAD%MERG-ED

+NUDSEN#7/MLAND4#LOPTON07ESTHEIM!!BRAHAM743TORROW!"-C#ORD*.OWAK2-!UMONT-#$UC0(OLLANDER*%7U!("-C#ULLOUGH0!-AISEL!3$IAGNOSTICVALUEOF"TYPENATRIURETICPEPTIDEANDCHESTRADIOGRAPHIClNDINGSINPATIENTSWITHACUTEDYSPNEA!M*-ED

-C#ORD*-UNDY"*(UDSON-0-AISEL!3(OLLANDER*%!BRAHAM743TEG0'/MLAND4+NUDSEN#73ANDBERG+2-C#ULLOUGH0!FORTHE"REATHING.OT0ROPERLY-ULTINATIONAL3TUDY)NVESTIGATORS2ELATIONSHIPBETWEENOBESITYANDBTYPENATRIURETICPEPTIDELEVELS!RCH)NTERN-ED

-AISEL!(OLLANDER*%'USS$ETAL0RIMARYRESULTSOFTHERAPIDEMERGENCYDEPARTMENTHEARTFAILUREOUTPATIENTTRIAL2%$(/4AMULTICENTERSTUDYOFBTYPENATRIURETICPEPTIDELEVELSEMERGENCYDEPARTMENTDECISIONMAKINGANDOUTCOMESINPATIENTSPRESENTINGWITHSHORTNESSOFBREATH*!MER#OLL#ARDIOL

(ARRISON!-ORRISON,++RISHNASWAMY0ETAL"TYPENATRIURETICPEPTIDE".0PREDICTSFUTURECARDIACEVENTSINPATIENTSPRESENTINGTOTHEEMERGENCYDEPARTMENTWITHDYSPNEA!NN%MERG-EDn

(ORWICH4"0ATEL*-AC,ELLAN27ETAL#ARDIACTROPONIN)ISASSOCIATEDWITHIMPAIREDHEMODYNAMICSPROGRESSIVELEFTVENTRICULARDYSFUNCTIONANDINCREASEDMORTALITYINADVANCEDHEARTFAILURE#IRCULATION

3ILVER-!-AISEL!9ANCY#7-C#ULLOUGH0!"URNETT*#&RANCIS'3-EHRA-20EACOCK7&&ONAROW''IBLER7"-ORROW$!(OLLANDER*".0#ONSENSUS0ANEL!CLINICALAPPROACHFORTHEDIAGNOSTICPROGNOSTICSCREENINGTREATMENTMONITORINGANDTHERAPEUTICROLESOFNATRIURETICPEPTIDESINCARDIOVASCULARDISEASES#ONG(EART&AILURESUPPL


#OPYRIGHT%-#2%')NTERNATIONAL

/iii>i>`

`Vvi`

>iVi`i>i

vwViL>>Vi

iy`ii

vi,-

/,/ /"1/"* -/,/1, /, 9*,/ /

$OUGLAS-#HAR-$$IVISIONOF%MERGENCY-EDICINE7ASHINGTON5NIVERSITY

3T,OUIS-/

0ATHOPHYSIOLOGYAND(EMODYNAMIC!SSESSMENT)N THE PAST DECOMPENSATED HEART FAILUREWAS FELT TO BE DUE TO VOLUME OVERLOADAND IMPAIRED FORWARD mOW 4REATMENTWASFOCUSEDONMAXIMIZINGCARDIACOUTPUT)THASNOWBECOMEAPPARENTTHATINMOST !$(&PULMONARY EDEMA THERE ISINCREASED SYSTEMIC VASCULAR RESISTANCESUPERIMPOSEDONREDUCEDMYOCARDIALRESERVEBOTHSYSTOLICANDDIASTOLIC-ANYVARIABLESPLAYAROLEIN!$(&THATEXACERBATE LEFT VENTRICULAR ,6 DYSFUNCTIONAND LEAD TO DETERIORATION ,OW CARDIACOUTPUTRESULTSINDECREASEDRENALmOWANDSTIMULATESNEUROHORMONALACTIVATIONINCLUDINGTHERELEASEOFANGIOTENSIN))$ECREASEDCARDIACOUTPUTCAUSESPROGRESSIVEBLOODVOLUMEEXPANSIONFURTHERINCREASING,6lLLINGPRESSURESANDMYOCARDIALOXYGENCONSUMPTION(YPOTENSIONPROMOTES BARORECEPTOR ACTIVATION LEADING

TOINCREASEDSYMPATHETICTONEANDVASOCONSTRICTIONWHICHFURTHERINCREASESSYSTEMICVASCULAR RESISTANCE COMPROMISINGSYSTOLIC PERFORMANCE 4HERE IS MARKEDUPREGULATIONOFVASOCONSTRICTORSINCLUDING NOREPINEPHRINE ANGIOTENSIN )) ANDENDOTHELINALDOSTERONEANDARGININEVASOPRESSINRISECONTRIBUTINGTOTHESALTANDWATERRETENTION

4OCOUNTERBALANCETHEEFFECTSOFNEUROHORMONES RELEASED BY THE SYMPATHETICNERVOUS SYSTEM AND THE RENINANGIOTENSINALDOSTERONE SYSTEM 2!!3 AND TOMAINTAIN CIRCULATORY HOMEOSTASIS THEBODY PRODUCES A FAMILY OF VASODILATORANTIPROLIFERATIVENATRIURETICPEPTIDESTHATPLAY AN IMPORTANT ROLE IN HEART FAILURE!TRIAL AND "TYPE NATRIURETIC PEPTIDESARERELEASEDFROMTHEMYOCARDIUMINRESPONSETOINCREASEDATRIALNATRIURETICPEPTIDE AND VENTRICULAR "TYPE NATRIURETIC

/,"1/" !CUTELYDECOMPENSATEDHEARTFAILURE!$(&ISACOMMONREASONFORPATIENTSSEEKINGEMERGENCYDEPARTMENT%$CAREANDTHELEADING-EDICAREDIAGNOSISFORHOSPITALIZEDPATIENTS OVER THE AGE OF (OSPITAL READMISSION FOR HEART FAILURE IS COMMON APPROXIMATELYOFPATIENTSAREREADMITTEDWITHINDAYSANDWITHINMONTHS2ECENTADVANCESIN THEUNDERSTANDINGOF THECOMPLEXPATHOPHYSIOLOGICPROCESS THATEXACERBATEHEARTFAILUREHASLEDTOIMPROVEDDIAGNOSESANDEFFECTIVE%$TREATMENTOFTHISCLINICALENTITY

"/6-\ iVLi>ii>>V>i}iVV>>v>i

iwiiiv>`>>i>>vi>v


PEPTIDE".0STRESS 4HEYINCREASEGLOMERULARlLTRATION RATE '&2 INHIBIT SODIUM REABSORPTION ANDREDUCEVASCULARSMOOTHMUSCLETONECAUSINGADIURESISNATRIURESISANDBALANCEDARTERIALANDVENOUSDILATION !LL THESEEFFECTSCONTRIBUTE TOREDUCEDPLASMAVOLUMEBLOODPRESSUREANDVENTRICULARPRELOAD".0HASLUSITROPICRELAXINGEFFECTSANDMAYBEANTIlBROTICANDANTIPROLIFERATIVE )N!$(& THE RELEASEANDPRODUCTIONOFSTOREDNATRIURETICPEPTIDESARE INSUFlCIENTTOBALANCETHEmUIDRETENTIONOFTHE2!!3

2APID BEDSIDE ASSESSMENT OF!$(& CAN BE SIMPLIlEDBYPLACINGTHEPATIENTINTOONEOFFOURHEMODYNAMICPROlLES Q}iR 4WOKEYHEMODYNAMICPARAMETERS ARE THE PRESENCE OR ABSENCE OF ELEVATEDlLLINGPRESSURESWETORDRYANDADEQUACYOFPERFUSIONWARMORCOLD #ONGESTIONCORRESPONDSTOELEVATEDPULMONARYCAPILLARYWEDGEPRESSURE0#70

(YLGHQFHIRU&RQJHVWLRQ(OHYDWHG)LOOLQJ3UHVVXUH

2UWKRSQHD+LJK-XJXODU9HQRXV3UHVVXUH,QFUHDVLQJ6/RXG3(GHPD$VFLWHV5DOHV8QFRPPRQ$EGRPLQRMXJXODU5HIOX[9DOVDOYD6TXDUH:DYH

(YLGHQFHIRU/RZ3HUIXVLRQ

1DUURZ3XOVH3UHVVXUH3XOVXV$OWHUDWLRQV&RRO)RUHDUPVDQG/HJV0D\EH6OHHS\2EWXQGHG$&6,QKLELWRU5HODWHG6\PSWRPDWLF+\SRWHQVLRQ'HFOLQLQJ6HUXP6RGLXP/HYHO:RUVHQLQJ5HQDO)XQFWLRQ

$ %

/ &

:DUPDQG'U\ :DUPDQG:HW

&ROGDQG:HW&ROGDQG'U\

&RQJHVWLRQDW5HVW"

/RZ3HUIXVLRQDW5

HVW"

1R

1R

`ii`iv >]i]-ii7n\n{

ANDIMPAIREDPERFUSIONISSUGGESTEDBYALOWCARDIACINDEX'REATERTHANOFPATIENTSPRESENTINGWITH!$(&ARECONGESTEDWET4HEYMAYHAVEADEQUATEORREDUCEDPERFUSIONWITHTHEMAJORITYEXPERIENCINGELEVATED SYSTEMIC VASCULAR RESISTANCE #ONGESTIONELEVATED lLLING PRESSURE IN !$(& IS REPRESENTEDBY DYSPNEA AND ORTHOPNEA AND ELEVATED JUGULAR VENOUSPRESSURE2ALESWHILEAHELPFULSIGNAREABSENTIN OF PATIENTSWITH CHRONICALLY ELEVATED lLLINGPRESSURESDUETOPULMONARYLYMPHATICCOMPENSATION0ERIPHERALEDEMAISRELATIVELYINSENSITIVETOELEVATEDlLLINGPRESSURESANDASSOCIATEDWITHMANYNONCARDIACCAUSES4HETHIRDHEARTSOUND3WHILEASENSITIVEMARKERISRARELYAPPRECIATED4HEMOSTREADILYAVAILABLEINDICATOROFPERFUSIONISBLOODPRESSUREANDPULSEPRESSURE4HISRAPIDASSESSMENTSYSTEMALLOWSFORAPPROPRIATETARGETINGOFTHERAPYIN!$(&PATIENTS

$IAGRAMINDICATINGXTABLEOFHEMODYNAMICPROlLESFORPATIENTSPRESENTINGWITH HEART FAILURE-OST PATIENTS CAN BE CLASSIlED IN AMINUTEBEDSIDEASSESSMENTACCORDINGTOTHESIGNSANDSYMPTOMSSHOWNALTHOUGHINPRACTICESOMEPATIENTSMAYBEONTHEBORDERBETWEENTHEWARMANDWETANDCOLDANDWETPROlLES4HISCLASSIlCATIONHELPSGUIDEINITIALTHERAPYANDPROGNOSISFORPATIENTSPRESENTINGWITHADVANCEDHEARTFAILURE!LTHOUGHMOSTPATIENTSPRESENTINGWITHHYPOPERFUSIONALSOHAVEELEVATEDlLLINGPRESSURESCOLDANDWETPROlLEMANYPATIENTSPRESENTWITHELEVATEDlLLINGPRESSURESWITHOUTMAJORREDUCTION IN PERFUSION WARMANDWET PROlLE 0ATIENTS PRESENTINGWITHSYMPTOMSOFHEART FAILUREATRESTORMINIMALEXERTIONWITHOUTCLINICALEVIDENCEOFELEVATEDlLLINGPRESSURESORHYPOPERFUSIONWARMANDDRYPROlLESHOULDBECAREFULLYEVALUATEDTODETERMINEWHETHERTHEIRSYMPTOMSRESULTFROMHEARTFAILURE

/,/ /"1/"* -/,/1, /, 9*,/ /

$ETERMININGTHE%TIOLOGYOF!CUTE$ECOMPENSATIONAND3ETTING4REATMENT'OALS4HEETIOLOGIESOF!$(&AREMULTIFACTORIALBUTCANBEDIVIDEDINTOTWOCATEGORIES THEUNDERLYING THEHEART FAILUREANDTHEACUTEPRECIPITANTTHATRESULTSINDETERIORATIONFROMTHECHRONICCOMPENSATEDSTATE)NPATIENTSPRESENTINGFORTHElRSTTIME THE TWO COMPONENTS ARE IDENTICAL4HEMOST COMMON CAUSES OF HEART FAILUREARECORONARYARTERYDISEASEANDLONGSTANDINGHYPERTENSION /THERETIOLOGIESINCLUDEDILATEDHYPERTROPHICANDRESTRICTIVECARDIOMYOPATHIESMYOCARDITISPERICARDIALTAMPONADEVALVULARHEARTDISEASEANDSECONDARYEFFECTSOFPULMONARYANDMETABOLICDISORDERS 5NDERSTANDING THEUNDERLYINGETIOLOGYISIMPORTANTINHELPING TO DETERMINE IF THERE IS A REVERSIBLECOMPONENTPRESENT4HEEMERGENCYPHYSICIANMUSTBEAWAREOFNUMBEROFSPECIAL CAUSES OF HEART FAILURE THAT REQUIRECONSIDERATION WHEN MAKING THERAPEUTICDECISIONS )N SEVERE AORTIC STENOSIS IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSISOR HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHYANDPULMONARYHYPERTENSIONAGGRESSIVE AFTERLOAD REDUCTION CAN LEAD TOCARDIOVASCULARCOLLAPSEASTHESEPATIENTSCANNOTINCREASETHEIRFORWARDBLOODmOWINTHEFACEOFAlXEDMECHANICALLESION

'REATER THANOFPATIENTSPRESENTINGTOTHE%$WITH!$(&HAVEAPRIORDIAGNOSISOFHEARTFAILURE!NACUTEPRECIPITANT CAN OFTEN BE IDENTIlED %XACERBATIONORWORSENINGOFTHEUNDERLYINGCONDITIONCANBEDUETOMEDICATIONORDIETARYNONCOMPLIANCEORTHEDEVELOPMENTOFANEW OR COMPLICATING MEDICAL CONDITION

SUCHAS ISCHEMIADYSRHYTHMIAPULMONARY EMBOLUS OR INFECTION 4REATMENTDEPENDSONTHESEVERITYOFTHESYMPTOMSANDDECOMPENSATIONTIMECOURSE

4HERAPEUTICGOALSIN!$(&PATIENTSCANBEDIVIDEDINTHREEPHASES4HEPRIMARYGOALINTHE%$ISRESTORATIONOFOXYGENATION ORGAN PERFUSION AND TOTAL BODYmUID BALANCE 4HIS IS ACCOMPLISHED BYREVERSINGACUTEHEMODYNAMICABNORMALITIESANDRELIEVINGSYMPTOMS)NTERMEDIATE GOALS INCLUDEMINIMIZING ENDORGANDAMAGE REDUCING HOSPITALIZATION DURATION AND INITIATIONOF BENElCIALMEDICALTHERAPIES AND SHOULD COMMENCE IN THE%$,ONGTERMGOALSFOCUSONREDUCINGREADMISSION AND IMPROVING LONGTERMSURVIVAL WITH TREATMENT THAT DECREASESDISEASEPROGRESSION4HISOCCURAFTERTHEPATIENT LEAVES THE%$ 7HILENATIONALGUIDELINES EXIST FORMANY ACUTE CARDIOVASCULARCONDITIONSTHEREARENOCONSENSUS GUIDELINES FOR THE MANAGEMENT OF!$(& 'IVEN THE LACK OF RANDOMIZEDCONTROLLEDTRIALSCONSENSUSTHATINCORPORATESEVIDENCEBASEDLITERATUREANDEXPERTOPINIONSHOULDBEUSEDASGUIDELINES

!PPROACHTO)NITIAL4REATMENT/URIMPROVEDUNDERSTANDINGOFTHEETIOLOGYOFHEARTFAILUREANDITSPROGRESSIONHASIDENTIlEDTHE2!!3ANDNEUROHORMONALPATHWAYSAS TARGETSOF THERAPYANDMAYEXPLAIN THE BENElTS OF NEUROHORMONALBLOCKERS SUCH AS ANGIOCONVERTING ENZYME!#%INHIBITORSBETABLOCKERSALDOSTERONEBLOCKERSEGSPIRONOLACTONEANDSUPRAPHYSIOLOGICDOSESOFNATRIURETICPEPTIDES SUCHAS!.0AND".0 IN THETREATMENTOFHEARTFAILURE

/ii`>V

>>ii>ii

iiVi>LiVi

vii>i`w}

iii`

>`i>`i>V

viv

>V`

)NITIALTHERAPYSHOULDBEGUIDEDBYTHEPATIENTSHEMODYNAMICPROlLEQ}iR &ORPATIENTSWITHOUTEVIDENCEOFELEVATEDlLLINGPRESSURESORHYPOPERFUSION DRY AND WARM NO IMMEDIATEINTERVENTION IS NEEDED #ARE SHOULD FOCUS ONMAINTAININGSTABLEVOLUMESTATUSANDPREVENTINGDISEASEPROGRESSION 4HESEPATIENTSRARELYPRESENT TO THE%$ )N PATIENTSWITH ELEVATEDlLLINGPRESSURESBUTADEQUATEPERFUSIONWETANDWARMTHERAPYAIMS TODIURESE !SSUMING THEYAREALREADYRECEIVING!#%INHIBITORSTHEGOALISTOENHANCETHEIRDIURETICREGIMEN)NMOREADVANCEDCASES THE USE OF INTRAVENOUS LOOP DIURETICS ANDVASODILATORS SUCH AS NITROGLYCERIN OR NESIRITIDECAN ACCELERATE SYMPTOM RESOLUTION 4HE MAINCHALLENGE ISAVOIDINGHYPOTENSION )N THIS SITUATION INOTROPIC THERAPY IS CONTRAINDICATED &ORCONGESTEDELEVATEDlLLINGPRESSUREPATIENTSWITHCLINICALHYPOPERFUSIONWETANDCOLDITISUSUALLYNECESSARYTOhWARMUPINORDERTODRYOUTv&ORTHESEPATIENTSINWHOMREmEXRESPONSESSUPPORTTHEFAILINGCIRCULATION`BLOCKERSAND!#%INHIBITORSMAYNEEDTOBEWITHDRAWNUNTILSTABILIZATIONISACHIEVED,OWCARDIACOUTPUTISOFTENASSOCIATEDWITHHIGHSYSTEMICVASCULARRESISTANCEAND

$IWHUGLDJQRVLVRI$'+)LQLWLDWHWKHUDS\EDVHGRQSUHVHQWLQJVLJQVDQGV\PSRPV

$6LJQVDQG6\PSRPVRI9ROXPH2YHUORDG %6LJQVDQG6\PSRPVRI/RZ&DUGLDF2XWSXW

&0LOGYROXPHRYHUORDG

(0RGHUDWH6HYHUH9ROXPH2YHUORDG *0LOG0RGHUDWH -9HU\/RZ&DUGLDF2XWSXW

6%3!PP+J

2QDBEORFNHUFKURQLFDOO\"

,QDGHTXDWH5HVSRQH

&RQVLGHU9HU\/RZ&DUGLDF2XWSXW-

&RQVLGHU0RGHUDWH6HYHUH9ROXPH2YHUORDG(RU/RZ&DUGLDF2XWSXW%

,'REXWDPLQH,0LOULQRQH

',9'LXUHWLFV

.O

9ES

9ES

.O

),9'LXUHWLFV,99DVRGLODWRUV

,9IXURVHPLGH,IIXURVHPLGHJLYHQSUHYLRXVO\GRXEOHSUHYLRXV,9GRVHPD[PJ,IQRIXURVHPLGHJLYHQSUHYLRXVO\DQGVLJQVV\PSWRPVRIYROXPHRYHUORDGJLYHPJ,9DVGHVFULEHGDERYH

3/861HVLULWLGHMJNJ,9SXVKWKHQMJNJYHLQLQIXVLRQ251LWURJO\FHULQSJPLQLQIXVLRQWRDFKLHYHGHFUHDVHLQ3&:3GRVHRIMJPLQPD\EHQHFHVVDU\

,QDGHTXDWH5HVSRQHP/ZLWKLQKRXUV

MJNJPLQLQIXVLRQ$GMXVWGRVHUHQDOO\

MJNJPLQLQIXVLRQ0D\DOVRUHTXLUHYDVRSUHVVRUVIRU%3VXSSRUW

3XOPRQDU\DUWHU\FDWKHWHUSODFHG+LJK695+LJK3&:3/RZ&,6%3!PP+J

&RQVLGHUYDVRGLODWRUVDIWHULQLWLDWLRQRILQRWURSLFVXSSRUW

1DUURZSXOVHSUHVVXUH$OWHUHGPHQWDOVWDWXV3UHUHQDOD]RWHPLD&RROH[WUHPLWLHV

'HFUHDVHGXULQHRXWSXW,QDGHTXDWHUHVSRQVHWR,9GLXUHWLFV

2UWKRSQHD31''2(62%3LWWLQJHGHPD&KHVW[UD\SXORQDU\FRQJHVWLRQ5HFHQWZHLJKWJDLQ

,QFUHDVHG-9'6RU65DOHV+-5$-5l%13

,QDGHTXDWHUHVSRQVHWR,9GLXUHWLFV3UHUHQDOD]RWHPLD,QFUHDVHGR[\JHQUHTXLUHPHQWV&3$3RU%L3$3UHTXLUHPHQWV)DWLJXH,QSDWLHQWGLVSRVLWLRQXQFOHDU2XWSDWLHQWIXURVHPLGHGRVH!PGGDLO\6%3!PP+*

,9IXURVHPLGH2QSRIXURVHPLGHDWKRPH"*LYHWRWDOGRVHDV,9EROXVPD[PJ1RSRIXURVHPLGHDWKRPH"6&UVWDUWZLWKPJ,9SXVK6&U!VWDUWZLWKPJ,9SXVK

}iViìVi>iì>v>ii>i>},iiìviVi>*>>Vi{n\{

!*2 ABDOMINAL JUGULAR REmEX "I0!0 BILEVEL POSITIVE AIRWAYPRESSURE ".0 BNATRIURETIC PEPTIDE #) CARDIAC INDEX#0!0 CONTINUOUS POSITIVE AIRWAY PRESSURE $/% DYSPNEA ONEXERTION(*2HEPATOJUGULARREmEX*6$JUGULARVENOUSDISTENTION0#70 PULMONARY CAPILLARY WEDGE PRESSURE 0.$ PAROXYSMALNOCTURNAL DYSPNEA 3"0 SYSTOLIC BLOOD PRESSURE 3#R SERUMCREATININE 3/" SHORTNESS OF BREATH 362 SYSTEMIC VASCULARRESISTANCE


MAYIMPROVEWITHVASODILATORTHERAPYALONE 4HEREREMAINSCONTROVERSYABOUTTHEROLEOFINOTROPICVASODILATORAGENTSSUCHASDOBUTAMINEANDMILRINONEDUETOTHEINCREASEDRISKFORISCHEMICEVENTSANDTACHYARRHYTHMIAS0ATIENTSWITHLOWCARDIACOUTPUTWITHOUTEVIDENCE OF ELEVATED lLLING PRESSURE COLD AND DRY

MAY BE SURPRISINGLY STABLE AND DO NOT PRESENT WITHURGENTSYMPTOMS5NLESSTHEYHAVESUBNORMALlLLINGPRESSURESVOLUMEDEPLETEDOREXCESSIVEVASODILATIONTHEYOFTENDONOTIMPROVEACUTELY)NOTROPICINFUSIONWHILEHELPINGTHESYMPTOMSMAYLEADTODEPENDENCYANDTACHYPHYLAXIS

/,/ /"1/"* -/,/1, /, 9*,/ /

0HARMACOLOGIC/PTIONS!NIDEALAGENTFOR!$(&WOULDBEONETHATRAPIDLYREDUCES0#7RELIEVINGSYMPTOMSANDHYPOXIAINDUCESBALANCEDARTERIAL AND VENOUS DILATION LACKS POSITIVEINOTROPIC EFFECTS PROMOTES NATRIURESISANDDOESNTCAUSEREmEXNEUROENDOCRINEACTIVATION

$IURETICSARETRADITIONALLYUSEDTOREDUCEPRELOADTHEREBYIMPROVINGSYMPTOMSIN!$(&PATIENTS 4HEY DO NOT HAVE ANYDIRECTMYOCARDIALBENElTBUTACTIVATETHENEUROHORMONALSYSTEMLEADINGTOALDOSTERONEELEVATION$IURETICSHAVEBEENUSEDFORDECADESANDMOSTPROVIDERSAREVERYCOMFORTABLE WITH THEM DESPITE THE FACTTHAT THEY LACK OF EVIDENCE OF IMPROVEDMORTALITY)NTRAVENOUSFUROSEMIDECAUSESADECREASEIN0#70ANDRIGHTATRIALPRESSUREASARESULTOFVENODILATIONANDDIURESIS4HEREISACONCOMITANTDECREASEINSTROKEVOLUMEINCREASEINSYSTEMICVASCULARRESISTANCEANDPRONOUNCEDSPIKEINNEUROHORMONAL ACTIVATION )NCREASES INTHE2!!3ANDSYMPATHETICNERVOUSSYSTEM ACTIVATION NOREPINEPHRINE LEVELSCANBESEENSHORTLYAFTERFUROSEMIDEINFUSION

)NONE TRIAL OFHIGHDOSE LOOPDIURETICSCOMPARED TO LOW DOSE DIURETICS COMBINED WITH INTRAVENOUS VASODILATORSPATIENTS TREATED WITH HIGHDOSE FUROSEMIDE DID SIGNIlCANTLYWORSE IN ALL OUTCOME MEASURES ! RECENT ANALYSIS OFEIGHT SMALL TRIALS FOUND THAT THERE WASGREATER DIURESIS AND A BETTER SAFETY PROlLEIFDIURETICSWEREGIVENASACONTINUOUS INSTEAD OF BOLUS INFUSION 7HILEINTRAVENOUSDIURETICSPROMOTENATRIURESISANDDIURESISTHEYDOSOATTHEEXPENSEOFNEUROHORMONAL ACTIVATION AND SYSTEMIC

VASOCONSTRICTION THAT PREVENTS REDUCTIONOF VENTRICULAR lLLING PRESSURES$IURETICRESISTANCE IS A CLINICAL STATE IN WHICHDIURETIC RESPONSE IS DIMINISHED OR LOST4HISMAY BE CAUSED BY PRERENAL AZOTEMIA HYPONATREMIA SODIUM RETENTION ORALTEREDDIURETICPHARMACOKINETICS4HEREISACYCLEOFLOWCARDIACOUTPUTLEADINGTODIMINISHEDRENALPERFUSIONWHICHINTURNPRODUCES VOLUME OVERLOAD ANDWORSENSHEART FAILURE 4HESE DELETERIOUS EFFECTSARE EVEN MORE PRONOUNCED IN PATIENTSWITH UNDERLYING RENAL INSUFlCIENCY$IURETICREQUIREMENTSINCREASEASTHEHEARTFAILUREPROGRESSES

!RGININEVASOPRESSINISANEUROHORMONEPRODUCEDBYTHECENTRALNERVOUSSYSTEMINRESPONSETOCHANGESINSERUMOSMOLARITYSEVEREHYPOVOLEMIAORHYPOTENSION/NEAPPROACH TO ANTAGONIZING VASOPRESSINSACTIONISTOSELECTIVELYBLOCKITSRECEPTORRESULTINGINAQUARESISWITHOUTELECTROLYTEIMBALANCES OR NEUROHORMONAL STIMULATION 4HENOVEL COMPOUND TOLVAPTAN ISANANTAGONISTTHATCAUSESINCREASEDURINEOUTPUT AND DECREASES BODY WEIGHT ANDEDEMA/NE STUDY LOOKED ATWEIGHT REDUCTIONFOLLOWINGHOURSOFINFUSIONINPATIENTSWITH IMPAIREDVENTRICULAR FUNCTION%&4HEREWASNODIFFERENCEIN INHOSPITALMORTALITYORWORSENINGOFHEART FAILURE 4HIS NOVEL AGENT SHOWSPROMISEOFFACILITATINGmUIDLOSSWITHOUTADVERSESEQUELAEINPATIENTSWITHREDUCEDSYSTOLICFUNCTION

)NOTROPESHAVEBEENAMAINSTAYOFTHERAPYFOR!$(&BECAUSEOFTHEIRBENElCIALEFFECTS ON HEMODYNAMIC PARAMETERSNAMELY INCREASING CARDIAC CONTRACTILITYWHICHIMPROVESCARDIACOUTPUT)NOTROPESAREUSEDINFREQUENTLYINTHE%$DUE

>i>`Li

}ì`Li>i

i`>Vwi

qqqqqqq

iV>iLii

i`vìV>ì>`

ì>ii

Vv>Lii

ìiiv>V>

i>VviìViv

i`>


PRIMARILYTOLOGISTICALCONCERNS2ECENTLARGESTUDIESDEMONSTRATEDA LACKOFEFlCACY INMANY!$(&PATIENTSANDEXPOSEDSAFETYCONCERNS)NOTROPESINCREASEHEARTRATEANDMYOCARDIALOXYGENDEMANDAGGRAVATEISCHEMIAPRECIPITATEARRHYTHMIASANDCANCAUSEHYPOTENSION!TRIALCOMPARINGDOBUTAMINEVERSUSNESIRITIDEDEMONSTRATEDTHATDOBUTAMINEINCREASESVENTRICULAR ECTOPY AND VENTRICULAR TACHYCARDIA -ILRINONEFAILEDTODEMONSTRATESIGNIlCANTIMPROVEMENTSINLENGTHOFHOSPITALIZATIONSYMPTOMRELIEFORMORTALITYCOMPAREDTOPLACEBO)TWASHOWEVERASSOCIATEDWITHSUSTAINEDHYPOTENSIONAND TACHYARRHYTHMIAS INTHE/04)-%#(&TRIAL $OBUTAMINEISPREFERREDIN PATIENTS WHO ARE HYPOTENSIVE SYSTOLIC "0 MM(GSINCE IT EXERTS ITSEFFECTSBYSTIMULATING`ADRENERGICRECEPTORS(IGHERDOSESAREOFTENREQUIREDIN PATIENTS ON CHRONIC`BLOCKER THERAPY-ILRINONEISAPHOSPHODIESTERASEINHIBITORANDITSACTIONISNOTIMPACTEDBYCONCOMITANT`BLOCKERUSE -ILRINONEDOESNT INCREASE MYOCARDIAL OXYGEN CONSUMPTIONOR EFFECT HEART RATE TO THE SAME DEGREE THAT DOBUTAMINEDOES)NGENERALGIVENTHEIRINABILITYTOAFFECTOUTCOMEANDINCREASEDINCIDENCEOFADVERSEEFFECTSINOTROPICSUPPORTSHOULDBERESERVEDFORPATIENTSWITHVERYLOWCARDIACOUTPUT4HEYSHOULDONLYBEUSEDINTHE%$SETTINGONPATIENTSWITHSYMPTOMATICHYPOTENSIONUNTILFURTHERTHERAPYINTRAAORTICBALLOONPUMPCANBEINSTITUTED

#ALCIUM SENSITIZERS SUCH AS LEVOSIMENDAN PRODUCEINCREASED INOTROPY IN A CYCLIC !-0INDEPENDENTFASHIONBYINCREASINGTHESENSITIVITYOFTROPONIN#TOINTRACELLULAR IONIZED CALCIUM AS WELL AS PERIPHERALVASODILATION THROUGH THE VASCULAR +!40ASE CHANNELS !N EFFECTIVE POSITIVE INOTROPE LEVOSIMENDANINCREASESINSTROKEVOLUMEANDCARDIACINDEXANDDECREASES0#70 RIGHT ATRIALPRESSURESPULMONARYARTERIALPRESSURESANDMEANARTERIALPRESSURES)NTHISSTUDYTHEHEMODYNAMICEFFECTSWEREMAINTAINEDDURINGAHOURINFUSIONANDFORATLEASTHOURSAFTERDISCONTINUATION 7HEN LEVOSIMENDANWAS ADDED TODOBUTAMINEIN.EW9ORK(EART!SSOCIATIONCLASS)6

PATIENTS REFRACTORY TO DOBUTAMINE AND FUROSEMIDEOFPATIENTSGETTINGALLTHREEAGENTSCOMPAREDTONONE IN THE STANDARD GROUP EXPERIENCED A INCREASEINCARDIACINDEX4HISEXCITINGAGENTISINTHEEARLYCLINICALTRIALS

6ASODILATORSREDUCEPRELOADANDAFTERLOADENHANCINGVENTRICULARFUNCTIONANDCARDIACOUTPUTBYIMPROVINGRESTING HEMODYNAMICS6ASODILATORS REDUCE VENTRICULARlLINGPRESSURES 0#70 ANDPRELOAD ANDOVERTIMEMYOCARDIALOXYGENCONSUMPTION 6ASODILATORSALSO DECREASE SYSTEMIC VASCULAR RESISTANCE 362 ORAFTERLOAD REDUCE VENTRICULAR WORKLOAD INCREASESTROKEVOLUMEANDIMPROVECARDIACOUTPUT

.ITRATES IN PARTICULAR NITROGLYCERIN HAVE BEEN THElRSTLINEPREHOSPITALAND%$THERAPYFORPATIENTSWITHSEVERESYMPTOMS .ITRATESNITROGLYCERINANDNITROPRUSSIDE ACT BY INCREASING CYCLIC GUANOSINEMONOPHOSPHATE IN THEVASCULARSMOOTHMUSCLE LEADINGTOVASODILATION4HEY IMPROVE SYMPTOMSANDDECREASE0#70RELATIVELYQUICKLY.ITROGLYCERINUSEISLIMITEDBYFEAROFHYPOTENSIONANDNEEDFORTITRATIONSECONDARY TACHYPHYLAXIS YET IT IS FREQUENTLY UNDERDOSED.ITROGLYCERINHASDIRECTAFFECTSONLARGECORONARYARTERIESANDINCREASESCOLLATERALmOWMAKINGITAUSEFULINPATIENTSWITHMYOCARDIALISCHEMIA(OWEVERTHEREARE NO TRIALS LOOKING AT ITS OUTCOME EFlCACY.ITROPRUSSIDE WHILE EFlCACIOUS IS USED INFREQUENTLY DUETOCONCERNSABOUTTHIOCYANATETOXICITYESPECIALLYINTHEFACEOFHEPATICORRENALHYPOPERFUSIONDYSFUNCTION )TCANALSOPRECIPITATEPROFOUNDHYPOTENSIONEXACERBATEISCHEMIABYINDUCINGCORONARYSTEALANDREQUIRES INVASIVE MONITORING "OTH OF THESE AGENTSCAUSEREmEXACTIVATIONOFTHE2!!3ANDSYMPATHETICNERVOUSSYSTEMWHICHLIMITSTHEIRLONGTERMUSE

!NGIOTENSINCONVERTING ENZYME !#% INHIBITIONBLOCKSCONVERSIONOFANGIOTENSIN)INTOANGIOTENSIN))RESULTINGINDIMINISHEDSYSTEMICVASCULARRESISTANCEBLOODPRESSUREPRELOADANDAFTERLOAD!#%INHIBITORSALSOBLOCKTHEDEGRADATIONOFBRADYKININSANATURAL

/,/ /"1/"* -/,/1, /, 9*,/ /

LY OCCURRING VASODILATOR!#% INHIBITORTHERAPYINCREASESRENALPERFUSIONANDDECREASE RENALVASCULAR RESISTANCE IMPROVINGGLOMERULARlLTRATIONRATEBYINDUCINGVASODILATIONINBOTHAFFERENTANDEFFERENTARTERIOLES4HEMAJORDRAWBACKTOTHEUSEOF INTRAVENOUS !#% INHIBITORS SUCH ASENALAPRILATINTHEACUTESETTINGISITSPROPENSITYTOINDUCEHYPOTENSION)NTHESTABLEPATIENT THEAGENTSMAJOR LIMITATIONSARE RENAL INSUFlCIENCYANDANGIOEDEMA%NALAPRILAT HAS BEENUSED IN THE SETTINGOF!$(&SECONDARYTOUNCONTROLLEDHYPERTENSION/RAL!#%INHIBITORSARERECOMMENDED EARLY OUT FOR THOSE PATIENTSNOTALREADYRECEIVINGTHEM(OWEVERTHEPATIENTMUSTBEHEMODYNAMICALLYSTABLEBEFORETHESEAGENTSAREINITIATEDANDTHISLIMITSTHEIRAGGRESSIVEUPFRONTUSEINTHE%$!NGIOTENSINRECEPTORBLOCKERCANBESUBSTITUTEDINPATIENTSWHOCANTTOLERATE!#%INHIBITORS

2ECENTATTENTIONHASBEENFOCUSEDONTHEACUTE BLOCKADEOF DELETERIOUSNEUROHORMONES %NDOTHELIN %4 IS A VASOCONSTRICTOR PEPTIDE RELEASED FROM VASCULARENDOTHELIUM AND SMOOTHMUSCLE OF THERENALANDPULMONARYSYSTEMS4EZOSENTAN IS A HIGHLY SPECIlC AND POTENT %4RECEPTORANTAGONIST4HEREISADOSEDEPENDENTINCREASEINCARDIACINDEXDUETOVASODILATIONANDDECREASEIN0#70)NTHE 2)4: PROJECT TEZOSENTAN IMPROVEDHEMODYNAMICBUTNOTCLINICALOUTCOMEOFPATIENTSWITHACUTEHEARTFAILURE!RECENTTRIALEVALUATINGLOWERDOSESINHOSPITALIZED!$(&PATIENTSWITHDYSPNEADESPITEINITIAL TREATMENT SHOWED INCREASED CARDIAC INDEXANDDECREASED0#70WITHINHOURSATTHEMGHOURANDMGHOURTREATMENTGROUPSANDBYHOURSINTHE

MGHOURCOHORT4HEEFFECTCONTINUEDBEYOND TREATMENT DISCONTINUATION IN THE MGHOUR GROUP %NDOTHELIUM LEVELSWEREINCREASEDINTHEHIGHERDOSEGROUPSSUGGESTING SYMPATHETIC NERVOUS SYSTEMACTIVATIONBUTNOTINTHEMGHOURSUBSET 4EZOSENTANS EFFECT WHILE CLINICALLYSIGNIlCANT IS NOT PRESENTLY APPROPRIATEFORTHE%$GIVENITSDELAYEDONSET

4HENATRIURETICPEPTIDE FAMILY CONSISTSOFFOUR DISTINCT PEPTIDES !TRIAL NATRIURETICPEPTIDES!.0AND"TYPENATRIURETICPEPTIDES".0ARESTRUCTURALLYSIMILAR#TYPENATRIURETICPEPTIDES#.0AND$TYPENATRIURETICPEPTIDES$.0ARELESSWELLCHARACTERIZED!TRIALAND"TYPENATRIURETICPEPTIDESHAVEIMPORTANTCENTRALANDPERIPHERALSYMPATHOINHIBITORYEFFECTS$AMPENINGOFTHE BARORECEPTORS SUPPRESSED RELEASE OFCATECHOLAMINEFROMAUTONOMICNERVElNDINGS AND ESPECIALLY SUPPRESSION OF SYMPATHETICOUTmOWFROM THECENTRALNERVOUSSYSTEMHAVEALLBEENREPORTED

4HE LONGTERM CONTINUOUS INFUSION OF!.0 HAS BEEN SHOWN TO BE CLINICALLYUSEFULINPATIENTSWITHSEVEREACUTEHEARTFAILURE (EMODYNAMIC MEASUREMENTSEVALUATEDBY3WAN'ANZCATHETERSIGNIlCANTLY IMPROVEDWITH!.0 )NA RECENTSTUDY HEMODYNAMIC INDICES CHARACTERIZED BY DECREASES IN RIGHT ATRIAL PRESSUREMEAN PULMONARY ARTERIAL PRESSUREAND 0#70 AND AN INCREASE IN CARDIACINDEX WERE OBSERVED AFTER !.0 INFUSION ,EFT VENTRICULAR PERFORMANCEWASENHANCED WITHOUT THE DEVELOPMENT OFTOLERANCE 4HE ACTIVATION OF THE2!!3PROMOTES STRUCTURAL REMODELING OF THEHEART AND PROGRESSION OF HEART FAILURE!.0 THEREBY IMPROVED LEFT VENTRICULAR

ii>L

>vviVVi>`

Vi>i`V`iVi

v>`iiivviV]

V

`Liiii`

v>ii

V>`>V


FUNCTIONPOSSIBLYBYBLUNTINGMYOCARDIALREMODELING 7HILEAVAILABLE IN!SIAAND%UROPE!.0ISNOTAPPROVEDFORUSEINTHE5NITED3TATES

".0 IS AN ENDOGENOUS NEUROHORMONEPRODUCEDINTHEVENTRICLESINRESPONSETOINCREASEDWALLSTRESSTHATOCCURSFROMVOLUMEOVERLOADIN!$(&PATIENTS.ESIRITIDEISTHElRSTNATRIURETICPEPTIDEIDENTICAL TOENDOGENOUS".0 TOBEAVAILABLEINTHE5NITED3TATESFORTHETREATMENTOF!$(& 7ITHIN MINUTES OF ADMINISTRATIONNESIRITIDEPRODUCESSIGNIlCANTREDUCTIONS IN0#70RIGHTATRIALPRESSUREANDSYSTEMIC VASCULAR RESISTANCE ASWELL ASCONCOMITANT INCREASES IN STROKE VOLUMEANDCARDIACOUTPUT.ESIRITIDEHASADDITIONALADVANTAGESOVEROTHERVASODILATORSSUCHASNITROGLYCERININCLUDINGDIURESISNATRIURESISANDLUSITROPY4HEBENElCIALCORONARY ARTERY EFFECTS OF NITROGLYCERINAREALSOPRESENT INNESIRITIDE !DDITIONALLY NESIRITIDE LACKS THE PROARRHYTHMICANDTACHYCARDIASEENWITHINOTROPESANDMANYVASODILATORS

4HE6ASODILATION IN THE-ANAGEMENTOF!CUTE#ONGESTIVE(EAR&AILURE6-!#TRIAL COMPARED THE USE OF NESIRITIDE NITROGLYCERINORPLACEBOINADDITIONTOSTANDARDTHERAPYINPATIENTSWITH!$(&4HIS SAFETYANDEFlCACY TRIAL FOUND THATNESIRITIDE REDUCED0#70MORE THAN EITHER NITROGLYCERIN OR PLACEBO AT HOURSANDHOURS)MPROVEMENTSINDYSPNEAAND GLOBAL CLINICAL STATUS IN THE NESIRITIDETREATED PATIENTS WERE GREATER THANTHOSEINTHEPLACEBORECIPIENTSANDSIMILAR TO THOSE IN THE NITROGLYCERIN GROUP

.ESIRITIDESHEMODYNAMICEFFECTERSWERELONGLASTINGWITHOUTTHENEEDFORUPWARDTITRATIONWHEREASTITRATIONWASNECESSARYIN ORDER TO MAINTAIN NITROGLYCERINS EFFECT4HISWASMOSTSTRIKINGINTHESUBSETOFPATIENTSWITH RIGHTHEART CATHETERSONA CONSTANT DOSE OF NITROGLYCERIN WHERERAPIDATTENUATIONOFTHEDESIREDEFFECTANDRISEIN0#70WASSEENATHOURS

".0DOESNT INCREASEHEART RATEORPROVOKE ARRHYTHMIAS AND HAS NO INOTROPICEFFECTS 4HIS LACK OF ARRHYTHMOGENICITYIS ESPECIALLY IMPORTANT IN HEART FAILUREPATIENTSWITHATRIALlBRILLATIONANDTHOSEPREDISPOSED TO VENTRICULAR TACHYCARDIA4HE 02%#%$%.4 STUDY COMPARED THEPROARRHYTHMICEFFECTSOFDOBUTAMINEVERSUSDOSESOFNESIRITIDEINPATIENTS$OBUTAMINESIGNIlCANTLYINCREASEDVENTRICULAR TACHYCARDIA EVENTS .ESIRITIDEDIDNOTINCREASEHEARTRATEDESPITEGREATERREDUCTIONINBLOODPRESSURE"OTHAGENTSWEREEQUALLYEFFECTIVEINIMPROVINGSIGNSANDSYMPTOMSOFHEARTFAILURE#OMPAREDTODOBUTAMINENESIRITIDEREDUCEDDAYHOSPITALREADMISSIONSFORHEARTFAILUREANDHADLOWERMONTHMORTALITY

)NTHE0ROSPECTIVE2ANDOMIZED/UTCOMES3TUDY OF !CUTELY $ECOMPENSATED #ONGESTIVE (EART &AILURE 4REATED )NITIALLYIN /UTPATIENTS WITH .ATRECOR 02/!#4)/.STUDYPATIENTSWERERANDOMIZEDTOSTANDARDCAREORATLEASTHOURSOF NESIRITIDE INFUSION IN AN%$ OBSERVATIONSETTING)MPORTANTLYNONEOFTHESEPATIENTSWASSUBJECTTOINVASIVEOR)#5LEVELMONITORINGINTHE%$YETDIDWELL-ORTALITYRATESANDCOMPLICATIONSWERESIMILAR

*>ii>i

i>i`>i

i>

>>`Lii

Vi>i

iii

>`i>i`

/,/ /"1/"* -/,/1, /, 9*,/ /

BETWEEN THE TWO GROUPS .ESIRITIDE WASASSOCIATEDWITHAREDUCTIONINHOSPITALREADMISSIONWITHINDAYSCOMPAREDWITH STANDARD THERAPY AND A SUBSTANTIALDECREASE IN TOTAL LENGTH OF STAY OVER THEENSUINGMONTHSAFTERTHEINDEXVISIT

)N A POOLED ANALYSIS FROM THE 02/!#4)/. 6-!# AND .3'%4 TRIALSTHESHORTTERMRISKOFDEATHFROMNESIRITIDE WAS INVESTIGATED !S NONE OF THESTUDIES INCLUDED IN THE POOLED ANALYSISWEREPOWEREDTODETERMINEMORTALITYDIFFERENCESTHEREISNOCONCLUSIVEEVIDENCEOFHARM4HEMANUSCRIPTCONCLUDEDTHATWHEN COMPARED TO NONIONOTROPIC BASEDTHERAPYNESIRITIDEMAYBEASSOCIATEDWITHANINCREASEDRISKOFDEATH&URTHERSTUDYWITH MORTALITY OUTCOMES OF NESIRITIDECOMPARED TO CONVENTIONAL THERAPY HAVEYET TOOCCUR !SWITHANYNEW THERAPYTHEFAVORABLEATTRIBUTESMUSTBEWEIGHEDAGAINSTTHEPOTENTIALRISKS

%ARLY'OAL$IRECTED4HERAPY%ARLYGOALDIRECTEDTHERAPY%'$4APPROACH EMPHASIZES AGGRESSIVE UPFRONTTREATMENT BECAUSE PRELIMINARY EVALUATIONS HAVE SHOWN THAT PATIENTS TREATEDEARLY OUT TEND TO HAVE SHORTER HOSPITALSTAYS AND BETTER OUTCOMES THAN THOSEWHOSE INTERVENTION IS DELAYED )T AIMSTO ACHIEVE HEMODYNAMIC AND RESPIRATORY IMPROVEMENTPROMPT RELIEFOFSYMPTOMSENHANCEDDECISIONMAKINGIN THE %$ WITH AN EMPHASIS ON TIMELYTRANSITIONTOINPATIENTCAREIFINDICATEDEARLYINITIATIONOFTHERAPYALSOFACILITATESHOSPITAL DISCHARGE AND AVOIDANCE OFHIGHRESOURCEUTILIZATION#ARENEEDS

TO FOCUS ON RAPID INITIATION OF PROVENTHERAPIES THAT IMPROVEPATIENT SYMPTOMAND CARDIORESPIRATORY STATUS WITHOUTPLACINGTHEPATIENTATRISKFORIMMEDIATEARRHYTHMIAHYPOTENSIONISCHEMIAANDDELAYED WORSENING RENAL INSUFlCIENCYTOXICITYADVERSEEVENTS4HEREISGROWINGEVIDENCETHAT%'$4HASBOTHCLINICALANDECONOMICADVANTAGESOVERMORECONSERVATIVETREATMENTAPPROACHES

4HERE IS A SUBPOPULATION OF PATIENTSMODERATELY SICK REQUIRING MORE THAN AFEWHOURSOFCAREWHODONTNECESSARILYNEEDHOSPITALADMISSION4HEAVAILABILITYOF AN %$ OBSERVATION UNIT MAKES GOODCLINICALANDECONOMICSENSE%'$4CANBE INITIATED AND PATIENTS MONITORED FORIMPROVEMENT 0ATIENT SELECTION IS CRITICALLYIMPORTANTINDETERMININGWHOWILLMOST BENElT FROM AN OBSERVATION UNITSTAYMATCHINGACUITYWITHAVAILABLESERVICES'ENERALSELECTIONCRITERIAINCLUDETHEFOLLOWING ADEQUATESYSTEMICPERFUSIONNORMALMENTALSTATUS

EVIDENCEOFREASONABLEHEMODYNAMICSTABILITY(2ANDBEATSMINSYSTOLIC"0ANDMM(GOXYGENSATURATION

NOEVIDENCEOFACUTECARDIACISCHEMIABY%#'ORBIOMARKERS

CHESTXRAYlNDINGSCOMPATIBLEWITHTHEDIAGNOSISOFHEARTFAILURE

DIAGNOSISOF(&".0PGM,WITHOUTOTHERCONFOUNDINGMORBIDITIES

6>`>i`Vi

i>`>`>vi>`]

i>V}iV>

vV>`V>`>V

L}

i}i`>V

)NITIAL TREATMENT OF !$(& IS GENERALLYBASEDONTHEPRESENCEORABSENCEOFPULMONARY CONGESTION VOLUME OVERLOADANDANASSESSMENTOFPERFUSIONCARDIACOUTPUTQ}iR7HILETREATMENTALGORITHMS FOCUSONPARENTAL THERAPYDURING THE EARLY PHASE CONTINUATION OF THEPATIENTS CHRONIC HEART FAILURE MEDICATION INCLUDING BLOCKERS AND!#% INHIBITORSAREIMPORTANT -ILDCONGESTIONIMPROVES WITH INTRAVENOUS DIURETICS-ONITORINGOFURINEOUTPUTISCRITICAL&ORTHOSEWITHNORMALRENALFUNCTIONAGOALOFMLHRISACCEPTABLE0ATIENTSWITHINADEQUATERESPONSETOFUROSEMIDESHOULDBEASSESSEDFORTHEPRESENCEOFMODERATETOSEVEREVOLUMEOVERLOADANDVASODILATOR THERAPY SHOULDBE CONSIDERED )NTRAVENOUSNITROGLYCERINORNESIRITIDESHOULDBESTARTEDINPATIENTSWITHADEQUATEBLOODPRESSURE TO SPEED RELIEF OF CONGESTION)FNITROGLYCERIN ISUSED ITWILLBENECESSARYTOUPTITRATETHEINFUSIONFREQUENTLY0ATIENTSWITHEVIDENCEOFPOORPERFUSION


}i*>/>}iv/i>ii>>i

,i`Vi`>`ii`ivi]i>- }i`{n\n

}^>>Vii`V>-Vi

%HWDEORFNHUV

'LJR[LQLQRWURSHV

&DUGLDFUHV\QFKURQL]DWLRQ

WKHUDS\

$&(LQKLELWRUVDQJLRWHQVLQUHFHSWRUEORFNHUV

DOGRVWHURQHDQWDJRQLVWV

'LXUHWLFVDOGRVWHURQHDQWDJRQLVWVQHVLULWLGH

$&(LQKLELWRUVDQJLRWHQVLQUHFHSWRUEORFNHUVYDVRGLODWRUVDOSKDEORFNDGH

QHVLULWLGHH[HUFLVH

+($57

3HULSKHUDODUWHULHV

.LGQH\4REATMENTOPTIONSFORPATIENTSWITHHEARTFAILUREAFFECTTHEPATHOPHYSIOLOGICALMECHANISMSTHATARESTIMULATEDIN HEART FAILURE !NGIOTENSINCONVERTINGnENZYME !#%INHIBITORS AND ANGIOTENSINRECEPTOR BLOCKERS DECREASEAFTERLOADBYINTERFERINGWITHTHERENINnANGIOTENSINnALDOSTERONESYSTEMRESULTINGINPERIPHERALVASODILATATION4HEYALSOAFFECTLEFTVENTRICULARHYPERTROPHYREMODELINGANDRENALBLOODmOW!LDOSTERONEPRODUCTIONBYTHEADRENALGLANDSISINCREASEDINHEARTFAILURE)TSTIMULATESRENALSODIUMRETENTIONANDPOTASSIUMEXCRETIONANDPROMOTESVENTRICULARANDVASCULARHYPERTROPHY!LDOSTERONEANTAGONISTSCOUNTERACTTHEMANYEFFECTSOFALDOSTERONE$IURETICSDECREASEPRELOADBYSTIMULATINGNATRIURESISINTHEKIDNEYS$IGOXINAFFECTSTHE.A+n!40ASEPUMPINTHEMYOCARDIALCELLINCREASINGCONTRACTILITY )NOTROPESSUCHASDOBUTAMINEANDMILRINONE INCREASEMYOCARDIALCONTRACTILITY"ETABLOCKERS INHIBIT THESYMPATHETICNERVOUSSYSTEMANDADRENERGICRECEPTORS4HEYSLOWTHEHEARTRATEDECREASEBLOODPRESSUREANDHAVEADIRECTBENElCIALEFFECTONTHEMYOCARDIUMENHANCINGREVERSEREMODELING3ELECTEDAGENTSTHATALSOBLOCKTHEALPHAADRENERGICRECEPTORSCANCAUSEVASODILATATION6ASODILATORTHERAPYSUCHASCOMBINATIONTHERAPYWITHHYDRALAZINEANDISOSORBIDEDINITRATEDECREASESAFTERLOADBYCOUNTERACTINGPERIPHERALVASOCONSTRICTION#ARDIACRESYNCHRONIZATIONTHERAPYWITHBIVENTRICULARPACINGIMPROVESLEFTVENTRICULARFUNCTIONANDFAVORSREVERSEREMODELING.ESIRITIDEBRAINNATRIURETICPEPTIDEDECREASESPRELOADBYSTIMULATINGDIURESISANDDECREASESAFTERLOADBYVASODILATATION%XERCISEIMPROVESPERIPHERALBLOODmOWBYEVENTUALLYCOUNTERACTINGPERIPHERALVASOCONSTRICTION)TALSOIMPROVESSKELETALMUSCLEPHYSIOLOGY

/,/ /"1/"* -/,/1, /, 9*,/ /

SHOULDBECONSIDEREDFOR INOTROPICSUPPORT$OBUTAMINE SHOULDBE STARTED INPATIENTSWITH LOWCARDIACOUTPUTANDSYSTOLICBLOODPRESSUREMM(G4HEYMAY REQUIRE VASOPRESSOR SUPPORT IF HYPOTENSIONDEVELOPS0ATIENTSWITHLOWCARDIACOUTPUTBUTADEQUATEBLOODPRESSUREMAYBENElTFROMMILRINONEESPECIALLYIFTHEYAREALREADYTAKINGBETABLOCKERS4HOSEREQUIRINGINOTROPICSUPPORTWILLREQUIREADMISSIONTOANINTENSIVECAREUNIT4HOSERECEIVINGVASODILATORSCANOFTENBEMANAGEDINALESSACUTESETTINGTELEMETRYOR%$OBSERVATIONUNIT0RELIMINARYANALYSISFROMTHE!$(%2%REGISTRY INDICATED THAT LENGTHOF STAYWASREDUCEDBYUP TOA THIRD INPATIENTS RECEIVINGVASOACTIVEAGENTSVASODILATORSNESIRITIDEORINOTROPESINTHE%$OROBSERVATIONUNIT COMPAREDWITHPATIENTSWHOHADVASOACTIVETHERAPYINITIATEDINTHEHOSPITAL4HISEARLYINITIATIONOFEMERGENCYDEPARTMENTTHERAPYISASSOCIATEDWITHLOWERHOSPITALMORTALITYDECREASEDFREQUENCYOFINVASIVEPROCEDURESANDDECREASED)#5LENGTHOFSTAY4HUSEARLYTARGETEDVASOACTIVETHERAPYINTHE!$(&PATIENTSEEMSTOBEVERYPROMISING

-1,9)NTHEMAJORITYOFPATIENTSWHOPRESENTTOTHE%$WITH!$(&INITIALTHERAPYWITHOXYGENANDDIURETICSWILLNOT ADEQUATELY REDUCE lLLING PRESSURES OR IMPROVECARDIACOUTPUTENOUGHTOIMPROVESYMPTOMS)NOTROPESIMPROVESYMPTOMSINTHESHORTTERMBUTAREDELETERIOUS IN THE LONGRUN6ASODILATORS ARE FREQUENTLYNECESSARY AS THEY ADDRESS THE PRIMARY UNDERLYINGPATHOPHYSIOLOGYOFHEART FAILURE .ITROGLYCERINANDNITROPRUSSIDEAREEFFECTIVEBUTTHEIRUSEISHAMPEREDBYADVERSEEFFECTSAND LIMITATIONS .ATRIURETICPEPTIDES SUCH AS NESIRITIDE WITH THEIR NEUROHORMONALANTAGONISMMAYOFFERSEVERALBENElTSOVERCONVENTIONALVASODILATORSANDINOTROPESFORTHETREATMENTOF!$(&)THASBEENSHOWNTHATNESIRITIDECANBEUSEDSAFELYINTHE%$ANDUPFRONTUSECANREDUCEHOSPITALLENGTHOFSTAY

.EWPHARMACOLOGICALAGENTSUNDER INVESTIGATIONATTEMPT TO ENHANCE OUR UNDERSTANDING OF ABNORMALNEUROENDOCRINEFUNCTIONINHEARTFAILURE"YSPECIlCALLYTARGETINGKEYPOINTSSUCHASTHEACTIVATIONANDFEEDBACKPROCESSTHEYMAYPREVENTDISEASEPROGRESSION AND ACUTE DECOMPENSATION 7HILE WE AWAITNEW TREATMENT MODALITIES CURRENT %$ EFFORTS MUSTFOCUSONTHEEARLYIMPLEMENTATIONOFEFFECTIVESTRATEGIESTOIMPROVESYMPTOMSANDCORRECTTHEUNDERLYINGPHYSIOLOGY

,,

- !GHABABIAN26!CUTELYDECOMPENSATEDHEARTFAILURE

OPPORTUNITIESTOIMPROVECAREANDOUTCOMESINTHEEMERGENCYDEPARTMENT2EV#ARDIOVASC-EDSUPPL3

-AGNER**2OYSTON$(EART&AILURE"R*!NESTH &ONAROW'#4HETREATMENTTARGETSINACUTEDECOMPENSATEDHEART

FAILURE2EV#ARDIOVASC-ED3 .OHRIA!,EWIS%3TEVENSON,7-EDICALMANAGEMENTOF

ADVANCEDHEARTFAILURE*!-! 6ANDERHEYDEN-"ARTUNEK*'OETHALS-"RAINANDOTHER

NATRIURETICPEPTIDESMOLECULARASPECTS%UR*(EART&AIL

3TRAIN7$4HEUSEOFRECOMBINANTHUMAN"TYPENATRIURETICPEPTIDEINTHEMANAGEMENTOFACUTEDECOMPENSATEDHEARTFAILURE)NT*#LIN0RACT

(OLLANDER*0HARMACOLOGICMANAGEMENTOPTIONSINTHEEMERGENCYDEPARTMENT!DVIN(EART&AIL

6ANDER7AL-(*AARSMA4VAN6ELDHUISEN$*.ONCOMPLIANCEINPATIENTSWITHHEARTFAILUREHOWCANWEMANAGEIT%UR*(EART&AIL

7ELSCH*D(EISER2-3CHOOLER-0ETAL#HARACTERISTICSANDTREATMENTOFPATIENTSWITHHEARTFAILUREINTHEEMERGENCYDEPARTMENT*%MERG.URS

3HARMA-4EERLINK*2!RATIONALAPPROACHFORTHETREATMENTOFACUTEHEARTFAILURECURRENTSTRATEGIESANDFUTUREOPTIONS#URR/PIN#ARDIOL

$I$OMENICO2*0ARK(93OUTHWORTH-2ETAL'UIDELINESFORACUTEDECOMPENSATEDHEARTFAILURETREATMENT!NN0HARMACOTHER

#ODY2#LINICALTRAILSOFDIURETICTHERAPYINHEARTFAILURERESEARCHDIRECTIONSANDCLINICALCONSIDERATIONS*!M#OLL#ARDIOL!!

+UBO3(#LARK-,ARAGH*(ETAL)DENTIlCATIONOFNORMALNEUROHORMONALACTIVITYINMILDCONGESTIVEHEARTFAILUREANDSTIMULATINGEFFECTOFUPRIGHTPOSTUREANDDIURETICS!M*#ARDIOL

#OTTER'-ETZKOR%+ALUSKI%ETAL2ANDOMIZEDTRIALOFHIGHDOSEISOSORBIDEDINITRATEPLUSLOWDOSEFUROSEMIDEVERSUSHIGHDOSEFUROSEMIDEPLUSLOWDOSEISOSORBIDEDINITRATEINSEVEREPULMONARYEDEMA,ANCET

3ALVADOR$2+2EY.22AMOS'#0UNZALAN&%2#ONTINUOUSINFUSIONVERSUSBOLUSINJECTIONOFLOOPDIURETICSINCONGESTIVEHEARTFAILURE#OCHRANE$ATABASE3YSTEMATIC2EVIEWS#$

'HEORGHIADE-.IAZI)/UYANG*ETAL6ASOPRESSIN6RECEPTORBLOCKADEWITHTOLVAPTANINPATIENTSWITHCHRONICHEARTFAILURERESULTSFROMADOUBLEBLINDRANDOMIZEDTRIAL#IRCULATION

3TEVENSON,7#LINICALUSEOFINOTROPICTHERAPYFORHEARTFAILURELOOKINGBACKWARDORFORWARD#IRCULATION

"URGER!*(ORTON$0,E*EMETEL4ETAL%FFECTOFNESIRITIDEANDDOBUTAMINEONVENTRICULARARRHYTHMIASINTHETREATMENTOFPATIENTSWITHACUTELYDECOMPENSATEDCONGESTIVEHEARTFAILURETHE02%#%$%.4STUDY!M(EART*

#UFFE-3#ALIFF2-!DAMS+&ETAL3HORTTERMINTRAVENOUSMILRINONEFORACUTEEXACERBATIONOFCHRONICHEARTFAILURE*!-!

+IVIKKO-,EHTONEN,#OLUCCI733USTAINEDHEMODYNAMICEFFECTSOFINTRAVENOUSLEVOSIMENDAN#IRCULATION

.ANAS*.0APAZOGLOU004ERROVITIS*6ETAL(EMODYNAMICEFFECTSFLEVOSIMENDANADDEDTODOBUTAMINEINPATIENTSWITHDECOMPENSATEDADVANCEDHEARTFAILUREREFRACTORYTODOBUTAMINEALONE!M*#ARDIOL

-OAZEMI+#HANA*7ILLARD!-+OCHERIL!')NTRAVENOUSVASODILATORTHERAPYINCONGESTIVEHEARTFAILURE$RUGS!GING

4ORRE!MIONE'9OUNG*"#OLUCCI73ETAL(EMODYNAMICANDCLINICALEFFECTSOFTEZOSENTANANINTRAVENOUSDUALENDOTHELINRECEPTORANTAGONISTINPATIENTSHOSPTIALIZEDFORACUTEDECOMPENSATEDHEARTFAILURE*!M#OLLL#ARDIOL

#OTTER'+ALUSKI%3TANGL+ETAL4HEHEMODYNAMICANDNEUROHORMONALEFFECTSOFLOWDOSETEZOSENTANANENDOTHELIN!"RECEPTORANTAGONISTINPATIENTSWITHACUTEHEARTFAILURE%UR*(EART&AIL

DE$ENUS30(ARAND#7ILLIAMSON$2"RAIN.ATRIURETICPEPTIDEINTHEMANAGEMENTOFHEARTFAILURE#HEST

+ASAMA34OYAMA4+UMAKURA(ETAL%FFECTSOFINTRAVENOUSATRIALNATRIURETICPEPTIDEONCARDIACSYMPATHETICNERVEACTIVITYINPATIENTSWITHDECOMPENSATEDCONGESTIVEHEARTFAILURE*.UCL-ED

#OHN*.&ERRARI23HARPE.#ARDIACREMODELINGCONCEPTSANDCLINICALIMPLICATIONSnACONSENSUSPAPERFROMANINTERNATIONALFORUMONCARDIACREMODELING*!M#OLL#ARDIOL

6-!#INVESTIGATORS)NTRAVENOUSNESIRITIDEVSNITROGLYCERINFORTREATMENTOFDECOMPENSATEDCONGESTIVEHEARTFAILUREARANDOMIZEDCONTROLLEDTRIAL*!-!

3ILVER-!(ORTON$0#HALI*+%LKAYAM5%FFECTOFNESIRITIDEVERSUSDOBUTAMINEONSHORTTERMOUTCOMESINTHETREATMENTOFPATIENTSWITHACTUELYDECOMPENSATEDHEARTFAILURE!M*#OLL#ARDIOL

0EACOCK7&%MERMAN#,THE02/!#4)/.STUDYGROUP3AFETYANDEFlCACYOFNESIRITIDEINTHETREATMENTOFDECOMPENSATEDHEARTFAILUREINOBSERVATIONPATIENTS*!M#OLL#ARDIOL!

#OLUCCI73%LKAYAM5(ORTON$ETAL)NTRAVENOUSNESIRITIDEANATRIURETICPEPTIDEINTHETREATMENTOFDECOMPENSATEDCONGESTIVEHEARTFAILURE.ESIRITIDE3TUDY'ROUP.%NGL*-ED

3ACKNER"ERNSTEIN*$+OWALSKI-&OX-ETAL3HORTTERM2ISKOF$EATH!FTER4REATMENT7ITH.ESIRITIDEFOR$ECOMPENSATED(EART&AILURE!0OOLED!NALYSISOF2ANDOMIZED#ONTROLLED4RIALS*!-!

3ALTZBERG-4"ENElCIALEFFECTSOFEARLYINITIATIONOFVASOACTIVEAGENTSINPATIENTSWITHACUTEDECOMPENSATEDHEARTFAILURE2EV#ARDIOVASC-EDSUPPL

0EACOCK7&(EART&AILURE-ANAGEMENTINTHEEMERGENCYDEPARTMENTOBSERVATIONUNIT0ROGIN#ARDIOVAS$IS

%MERMAN#,0EACOCK7&THE!$(%2%INVESTIGATORS%VOLVINGPATETERSOFCAREFORDECOMPENSATEDHEARTFAILUREIMPLICATIONSFROMTHE!$(%2%REGISTRYDATABASE!CAD%MERG-ED

9OUNG*".EWTHERAPEUTICCHOICESINTHEMANAGEMENTOFACUTECONGESTIVEHEARTFAILURE2EV#ARDIOVASC-ED3



/6"6 ,"" * / "-- /,/ /"\-1,9"/ *" - -1-* ,*",/

/,"1/" !".0EXPERTCONSENSUSPANELCONSISTINGOFINDIVIDUALSWITHBASICMETHODOLOGICANDCLINICALEXPERTISEWASCONVENEDINTOCREATEASUMMARYDOCUMENTTOHELPGUIDETHECLINICIANONTHERECENTEXPLOSIONOFNATRIURETICPEPTIDE.0DATA4HISDOCUMENTCONTAINS THE DATA FROM THEIR RECOMMENDATIONS MOST APPLICABLE TO THE EMERGENCYPHYSICIAN

.ATRIURETIC0EPTIDE0HYSIOLOGY-ORETHANAPUMPTHEHEARTISACRITICALENDOCRINE ORGAN FUNCTIONING WITH OTHERPHYSIOLOGICAL SYSTEMS TO CONTROL mUIDVOLUME -YOCYTES MANUFACTURE A FAMILYOFPEPTIDEHORMONESTERMEDTHE.0SREPRESENTED BY ATRIAL NATRIURETIC PEPTIDE!.0 AND "TYPE NATRIURETIC PEPTIDE".02ELEASEOFTHE.0SISSTIMULATEDBY VOLUME OVERLOAD AND PHYSIOLOGICALLY THEYHAVEPOWERFULDIURETICNATRIURETICANDVASCULARSMOOTHMUSCLERELAXING ACTIONS )MPORTANTLY THEY ALSO SERVEASANTAGONISTSTOTHESYMPATHETICNERVOUSSYSTEM AND THE RENINANGIOTENSINALDOSTERONEAXIS 2!!32ELEASEOF.0SRESULTSFROMCARDIACWALLSTRETCHVENTRICULARDILATIONORINCREASEDPRESSURESFROMCIRCULATORYVOLUMEOVERLOAD4HEEFFECTSOF.0SRESULTINLOWERINGBLOODVOLUMEANDPRESSURE

".0 IS DERIVED FROM A PRECURSOR PREPRO".0WHICHUNDERGOESSEVERALCLEAV

"/6-\ $ISCUSSTHEAPPLICATIONANDLIMITATIONSOF".0TESTINGINTHEEMERGENCYSETTING $ESCRIBETHEAPPROPRIATECANDIDATEFOR".0THERAPY

7&RANK0EACOCK-$$EPARTMENTOF%MERGENCY-EDICINE4HE#LEVELAND#LINIC&OUNDATION

#LEVELAND/(

/6"6 ,"" * / "-- /,/ /"\-1,9"/ *" - -1-* ,*",/

AGES 4HE ASSAY RELEVANT PRODUCTS ARETHE INERT.TERMINALPRO".0FRAGMENTAND PHYSIOLOGICALLY ACTIVE ".0 ".0SAREPREFERENTIALLYPRODUCEDANDSECRETEDBYTHECARDIACVENTRICLESALTHOUGHmUIDOVERLOADMAYCAUSERAPID".0MANUFACTUREINBOTHHEARTCHAMBERS4HEPRIMARYFUNCTIONOF.0SISTODEFENDAGAINSTVOLUMEOVERLOAD!FTERRELEASEINTOCIRCULATION".0ACTIONSAREMODULATEDATTARGETSITES BY SPECIlC CELL MEMBRANE RECEPTORSTERMED!"AND#WHICHMEDIATEPHYSIOLOGICAL ACTIONS BY CYCLIC '-0#YCLIC'-0HASPOTENTVASODILATORYACTIONS".0 ALSO CAUSES AN INTRAVASCULARmUIDSHIFTFROMTHECAPILLARYBEDINTOTHEINTERSTITIUMWHICHCONTRACTS INTRAVASCULARVOLUMEANDDECREASES"0)NADDITION".0ISA2!!3ANTAGONISTWHEREITCOUNTERACTS SODIUM CONSERVATION VASOCONSTRICTIONANDVOLUMERETENTION".0ALSO INHIBITS THE RELEASE OF RENIN FROMKIDNEYCELLSANDALDOSTERONE FROMADRE

/iivviVv *

ii}

L`i

>`ii

#/.3%.35334!4%-%.43'%.%2!,#/--%.43

4HELABORATORYSHOULDPERFORM".0TESTINGONACONTINUOUSHOURBASISWITHATURNAROUNDTIME4!4OFMINUTESORLESS4HE4!4ISDElNEDASTHETIMEFROMBLOODCOLLECTIONTONOTIlCATIONOFRESULTTOPHYSICIANORCAREGIVER%ITHERCENTRALLABORATORYINSTRUMENTATIONORPOINTOFCARETESTINGSYSTEMSAREACCEPTABLE

% )NCONSIDERING.0MEASUREMENTSONENEEDSTOCAREFULLYCONSIDERLABORATORYANDBIOLOGICVARIATIONINCLUDINGGENDERSEXOBESITYANDRENALFUNCTION

% 4HERESULTSOFNATRIURETICTESTINGISDEPENDENTONTHETYPEOFTESTYOUAREOBTAINING.TERMINALPRO".0ANDBIOACTIVE".0ARE./4INTERCHANGEABLE


NALCELLS".0ISPRIMARILYMETABOLIZEDBYTHE.02#RECEPTORALTHOUGHSOMEADDITIONALDEGRADATIONMAYOCCURBYNEUTRALENDOPEPTIDASE.EUTRALENDOPEPTIDASE HAS AWIDE TISSUE DISTRIBUTION INCLUDING ADIPOSEKIDNEYSLUNGANDBRAIN}i

QUIRESMINUTESTOPERFORMANDREPORTS".0LEVELSFROM TOPGM,4HISASSAY IS RATEDASMODERATELY COMPLEX ASSAY PER #LINICAL ,ABORATORY )MPROVEMENT!MENDMENTS#,)!REGULATIONS

+HPRG\QDPLF%DODQFHGYDVRGLODWLRQ

9HLQV$UWHULHV&RURQDU\DUWHULHV

1HXURKXPRUDO$OGRVWHURQH(QGRWKHOLQ1RUHSLQHSKULQH

5HQDO'LXUHVLV1DWULXUHVLV

&DUGLDF/XVLWURSLF$QWLILEURWLF$QWLUHPRGHOLQJ

0DUFXV/6HWDO&LUFXODWLRQ=HOOQHU&HWDO$P-3K\VLROSW++$EUDKDP:7HWDO-&DUG)DLO&ODUNVRQ3%0HWDO&LUFXODWLRQ7DPXUD1HWDO3URF1DWO$FDG6FL86$

zz

zzzzzzzzzzzzzzzzzzzz

zzzzzzzz

zz

6 3 . 0 9 4 * 6*&)*5.0'5 , 6 6

66*/*&. 9 /

55+

z6 z6

}i */-

"IOLOGIC$ETERMINANTSON".0-EASUREMENTS"LOODLEVELSOF.0SAREAFFECTEDBYAVARIETYOFFACTORSINCLUDING CIRCADIAN RHYTHM AGE EXERCISE AND BODYPOSTURE-ANYDRUGSINCLUDINGDIURETICSANGIOTENSINCONVERTINGENZYMEINHIBITORSADRENERGICAGONISTSSEXANDTHYROIDHORMONESGLUCOCORTICOIDSSODIUMINTAKEANDOTHERCONDITIONSIMPACTLEVELS".0INCREASESWITHAGE AND GENDER "ASELINE AND PATHOLOGIC LEVELS AREHIGHER INWOMEN4HEAGE INDUCED".0 INCREASEMAYBEDUETOTHEDECLINEINMYOCARDIALFUNCTIONORTODECREASEDCLEARANCE

".0!SSAY)TSHOULDBEMADECLEARTHAT THE".0ASSAYISNOTASTANDALONETEST)TSGREATESTVALUEISWHENITISUSEDWITHTHEPHYSICIANSCLINICALJUDGMENTANDWITHOTHERAPPROPRIATETESTING4HE4RIAGE".0ASSAYSYSTEMISTHE ONLY &$! APPROVED POINTOF CARE ASSAY )T RE

".0FOR$IAGNOSISOF(EART&AILURE$ESPITE ADVANCES IN OUR UNDERSTANDING OF HEART FAILURE (&PATHOPHYSIOLOGY DIAGNOSIS ISSTILL DIFlCULT 7HILE EMERGENCY DEPARTMENT %$ DIAGNOSISNEEDSTOBERAPIDANDACCURATETHE SIGNS AND SYMPTOMS OF (&ARE NONSPECIlC 2ESPIRATORYDISTRESS CAN PRECLUDE OBTAININGTHEHISTORYANDDYSPNEAISNONSPECIlCINTHEELDERLYOROBESE2OUTINE LABS %#' AND XRAYSARE ALSO NOT ACCURATE ENOUGH TOALWAYSMAKETHECORRECTDIAGNOSIS

4HE"REATHING.OT0ROPERLYSTUDYWASALARGEMULTINATIONAL PROSPECTIVE STUDY USING".0 TO EVALUATEDYSPNEA IN DYSPNEIC%$ PATIENTS".0 LEVELSWERE MEASURED ON ARRIVAL AND PHYSICIANS ASSESSEDTHEPROBABILITYOFTHEPATIENTHAVING(&4WOCARDIOLOGISTSBLINDEDTOTHE".0LEVELREVIEWEDALLDATAAFTER HOSPITALIZATION TO PRODUCE A hGOLD STANDARDvCLINICALDIAGNOSIS".0LEVELSALONEMOREACCURATELYPREDICTEDTHEPRESENCEORABSENCEOF(&THANANYOTHERlNDING4HEPGM,CUTPOINTHADASENSITIVITY AND SPECIlCITY FOR A(&DIAGNOSIS )NMULTIVARIATEANALYSIS".0LEVELSALWAYSCONTRIBUTEDTOTHEDIAGNOSISEVENAFTERCONSIDERINGFEATURESOFTHEHISTORYANDPHYSICALEXAMINATION

".0 LEVELSMAY ALSO HELP IN DISPOSITION DECISIONS4HE2APID%MERGENCY$EPARTMENT(EART&AILURE/UTPATIENT2%$(/44RIALDEMONSTRATEDAhSTRONGDISCONNECTvBETWEEN THEPERCEIVEDSEVERITYOF(&ANDILLNESS SEVERITY AS DETERMINEDBY".0/N AVERAGEPATIENTSDISCHARGED FROM THE%$HADAHIGHER".0THANTHOSEADMITTEDPGM,VERSUSPGM,RESPECTIVELY".0ALSOPREDICTEDOUTCOMESOFPATIENTSDISCHARGEDHADA".0PGM,HOWEVERTHEREWASNOMORTALITYATDAYSIFTHE".0WASLESSTHANPGM,4HE3WISS"!3%,3TUDYEXAMINEDCOSTEFFECTIVENESSOFUSING".0THROUGHTHEDIAGNOSISANDHOSPITALIZATIONINACUTEDECOMPENSATEDHEARTFAILURE!$(&)NPATIENTS%$MEASUREMENTOF".0WASASSOCIATEDWITH A DECREASE IN HOSPITAL ADMISSIONSADAYDECLINEINLENGTHOFSTAYANDANSAVINGSWITHNOEFFECTSONMORTALITYORREHOSPITALIZATIONRATES

".0AND2ENAL&AILURE#HRONIC KIDNEY DISEASE #+$ INmUENCES THE CUTPOINTFOR".0)NGENERALAS#+$ADVANCESAHIGHER".0 CUTPOINT IS IMPLIED ! CUTPOINT OF APPROXIMATELY PGM, IS REASONABLE FOR THOSE WITH AN

#/.3%.35334!4%-%.453).'".04/(%,042)!'%%$0!4)%.437)4($930.%!

".0ISOFDIAGNOSTICUTILITYINTHEEVALUATIONOFPATIENTSWITHACUTEDYSPNEA4HUSINNEWPATIENTSPRESENTINGWITHDYSPNEATOANEMERGENCYSETTINGAHISTORYPHYSICALEXAMINATIONCHESTXRAYAND%#'SHOULDBEUNDERTAKENTOGETHERWITHLABORATORYMEASUREMENTSTHATINCLUDE".0#URRENTDATASUGGESTTHEFOLLOWINGGUIDELINES

% !S".0RISESWITHAGEANDISAFFECTEDBYGENDERCOMORBIDITYANDDRUGUSEITSHOULDNOTBEUSEDINISOLATIONFROMTHECLINICALCONTEXT

% )FTHE".0ISPGM,THEN(&ISHIGHLYUNLIKELY.06

% )FTHE".0ISPGM,THEN(&ISHIGHLYLIKELY006

% )FTHE".0ISnPGM,CONSIDERABASELINE".0ELEVATEDDUETOSTABLEUNDERLYINGDYSFUNCTIONRIGHTVENTRICULARFAILUREFROMCORPULMONALEACUTEPULMONARYEMBOLISMORRENALFAILURE

% 0ATIENTSMAYPRESENTWITH(&ANDANORMAL".0ORWITHLEVELSBELOWWHATISEXPECTEDINTHEFOLLOWINGSITUATIONSmASHPULMONARYEDEMAnHOURS(&UPSTREAMFROMTHELEFTVENTRICLESUCHASWITHACUTEMITRALREGURGITATIONFROMPAPILLARYMUSCLERUPTUREANDOBESEPATIENTSBODYMASSINDEX;"-)=

/6"6 ,"" * / "-- /,/ /"\-1,9"/ *" - -1-* ,*",/

ESTIMATEDGLOMERULARlLTRATION RATE '&2M,MINM5SINGTHISAPPROACH".0MAINTAINSAHIGHLEVELOFDIAGNOSTICUTILITYWITHANAREAUNDERTHE2/#CURVEOFACROSSALL#+$GROUPS

#ARDIOPULMONARY$ISEASE3OME NON(& CARDIOPULMONARY DISEASE MAY CAUSE".0ELEVATIONS4HESE INCLUDE CORPULMONALE LUNGCANCERPULMONARYEMBOLISM0%ANDPRIMARYPULMONARYHYPERTENSION)NTHESE".0MAYBEELEVATEDBUTNOTTOTHEEXTENTFOUNDIN!$(&)N0%".0MAYBEPROGNOSTICSINCEPATIENTSWITHA".0INTHEUPPERNORMALRANGEORPGM,HAVEAHIGHERMORTALITYRATE!LTHOUGH".0ISNOTANADEQUATESCREENINGTESTFOR0%INTHESETTINGOFASUSPECTEDORCONlRMEDEMBOLICEVENTA".0ELEVATIONIMPLIES26PRESSUREOVERLOADANDINCREASEDMORTALITYRISK&INALLYINPRIMARY PULMONARY HYPERTENSION".0 ELEVATIONS PARALLELTHEEXTENTOFPULMONARYHEMODYNAMICCHANGESANDRIGHT(&

0RESERVED3YSTOLIC&UNCTION03&(EART&AILURE$IASTOLICMYOCARDIALDYSFUNCTIONALSOKNOWNAS03&IS THECAUSEOF(&INASMANYOFOFCASESANDISALSOASSOCIATEDWITHHIGH".0".0HASBEENFOUNDTOBEAPPROXIMATELYHALFASHIGHIN03&ASINCASESOFSYSTOLICDYSFUNCTION

#/.3%.35334!4%-%.4".0).05,-/.!29!.$!33/#)!4%$#!2$)!#$)3%!3%

% )NAPPROXIMATELYOFPATIENTSWITHPULMONARYDISEASE".0ISELEVATEDIMPLYINGCOMBINED(&ANDLUNGDISEASECORPULMONALEORAMISDIAGNOSISWHENTHETRUEETIOLOGYOFDYSPNEAIS(&

% )NTHESETTINGOF0%".0ISELEVATEDINOFCASESANDISASSOCIATEDWITH26PRESSUREOVERLOADANDAHIGHERMORTALITY".0ISNOTDIAGNOSTICFORACUTE0%

% 0ULMONARYDISEASEWHICHRESULTSINPULMONARYHYPERTENSIONAND26PRESSUREORVOLUMEOVERLOADCANLEADTOELEVATED".0LEVELSUSUALLYINTHERANGEOFPGM,

#/.3%.35334!4%-%.43#/-/2")$)4)%3!.$30%#)!,)335%34(!4).&,5%.#%4(%).4%202%4!4)/./&".0,%6%,3

% ".0ISALTEREDWITHCHRONICRENALINSUFlCIENCYESTIMATED'&2M,MINWITHARECALIBRATIONOFTHECUTOFFVALUETOPGM,

% ".0ISHELPFULINTHEEVALUATIONOFDYSPNEAWHENITISVERYLOWORHIGH.4PRO".0HASGREATERCORRELATIONWITHE'&2THAN".0HENCELEVELSCANBEELEVATEDEVENWITHTHENORMALAGERELATEDDECLINEOFRENALFUNCTIONINTHEE'&2M,MINRANGE

% 7HENTHEE'&2ISBELOWM,MIN.TERMINALPRO".0CANBECONSIDERABLYELEVATEDANDINTHISSETTINGITSUTILITYINTHEEVALUATIONOF(&ISUNKNOWN

% "ASELINE".0LEVELSMIGHTTHEREFOREBEIMPORTANTINDIALYSISPATIENTSASCHANGESMOSTLIKELYREmECTVOLUMESTATUS4HUSAPREDIALYSIS".0MAYHELPDETERMINETHEAMOUNTOFVOLUMEWHICHSHOULDBEREMOVED

#/.3%.35334!4%-%.4".0).$)!34/,)#$93&5.#4)/.

% ".0MIGHTBEUSEDTODETECTPATIENTSWITHDIASTOLICDYSFUNCTION

% ".0CONCENTRATIONSABOVEAGEADJUSTEDCUTPOINTSMAYIDENTIFYELDERLYPATIENTSWITHDIASTOLICDYSFUNCTION


/BESITY/BESITY IS AN IMPORTANT RISK FACTOR FOR CORONARY ARTERYDISEASEAND(&0HYSIOLOGICALLYADIPOSETISSUEISRELATEDTOTHENATRIURETICCLEARANCERECEPTORAND OBESITY CAN INTERFERE WITH THE USUAL DIAGNOSTICAPPROACHTO(&-EHRADOCUMENTEDANINVERSERELATIONSHIPBETWEEN"ASAL-ETABOLIC)NDEX"-)AND".0,OWERLEVELSOF".0INTHEOBESE"-)+G-WERENOTEDDESPITESIMILARSEVERITYOF(&COMPAREDTOALEANCOHORTANDNEARLYOFOBESEPATIENTSHAD".0PGM,

#/.3%.35334!4%-%.4".0)./"%3)49

% 3INCEOBESEPATIENTSBODYMASSINDEX;"-)=KGMEXPRESSLOWERLEVELSOF".0FORANYGIVENSEVERITYOF(&CAUTIONSSHOULDBEEXERCISEDININTERPRETING".0LEVELSINSUCHPATIENTS

#/.3%.35334!4%-%.4".0).35$$%.$%!4(!#3!.$#!$

7HEN USED TOGETHER ".0 AND CARDIACTROPONIN PROVIDE A MORE EFFECTIVE TOOLFOR IDENTIFYINGPATIENTSAT INCREASED RISKFORCLINICALLYIMPORTANTCARDIACEVENTSRELATEDTO(&AND!#3-ULTIMARKERPANELSWITH".0ANDTROPONINARENOWAVAILABLEWHERE EACH OF THESE MARKERS PROVIDEUNIQUEANDINDEPENDENTOUTCOMEDATA

/6"6 ,"" * / "-- /,/ /"\-1,9"/ *" - -1-* ,*",/

".0AND!CUTE#ORONARY3YNDROMES!#3,ARGESTUDIESREPORT.0ELEVATIONSINUNSTABLEANGINAWITHOUTMYOCARDIALNECROSIS!SISCHEMIAMAYRESULTINONLYSMALL.0ELEVATIONSTHEIRSENSITIVITYANDSPECIlCITYAREINADEQUATEASAhRULEOUTvTOOL(OWEVERIFPRESENTANELEVATIONOF.0IN!#3ISAPOWERFULPREDICTOROFADVERSEEVENTS)NPATIENTS

".0PGM,

".0PGM,

".0PGM,

$AYS

}i,i> v * ìii` ii}iV ì>i V>i ì>i>v>i>>,iiìv

i}i`\n

GROUPEDINTO".0QUARTILESHOURSAFTER!#3ONSETAN INCREASING ".0 WAS ASSOCIATED WITH HIGHER MONTHMORTALITYANDTHISRELATIONSHIPPERSISTEDEVENWITHOUTEVIDENCEOF(&ORMYOCARDIALNECROSIS

".0AND0ROGNOSIS".0ELEVATIONISAPOWERFULMARKEROF(&PROGNOSIS)NPATIENTS FOLLOWED FORMONTHS AFTER AN%$VISITFORDYSPNEATHERELATIVERISKOFMONTH(&ADMISSIONORDEATHWASTIMESHIGHERIFTHE".0WASPGM,}i4HISWASCONlRMEDBYTHE6AL(E&4TRIALWHERETHELOWESTQUARTILEOF".0PGM,HADTHELOWESTALLCAUSEMORTALITYANDTHEHIGHESTQUARTILEPGM,HADTHEHIGHESTMORTALITYATMONTHS}i

".0AS4HERAPY7HEN!$(&OCCURSTHEBALANCEBETWEENVASOCONSTRICTORSANDENDOGENOUSVASODILATORS IS DISTURBED4HIS FORMS THE BASISAS TO WHY EXOGENOUS ".0 IS GIVEN ASTHERAPYDESPITE HIGH ENDOGENOUS LEVELSISANALOGOUSTOGIVINGINSULINFORINSULINRESISTANCE)N!$(&HIGHLEVELSOF".0OCCURASAhDISTRESSHORMONEvWHERESUPRANORMALLEVELSARENOLONGEREFFECTIVEAT MAINTAINING THE BALANCE OF VASOCONSTRICTION ANDVASODILATION(ENCE GIVING".0INTHEFORMOFNESIRITIDECANRESTORENEUROHORMONALHOMEOSTASIS

.0 ARE MUCH CLOSER TO IDEAL DRUGS FOR!$(&THANOTHERAGENTS4HEUSEOFNESIRITIDEISASSOCIATEDWITHREDUCEDlLLINGPRESSURES DECREASED PULMONARY VASCULAR RESISTANCE LOWERED CENTRAL VENOUSPRESSURESANDREDUCTIONINSYSTEMIC"04HEREISALSOINCREASEDCARDIACOUTPUTDUETOTHEUNLOADINGEFFECTOFVASODILATATIONBUTWITHOUTREmEXTACHYCARDIA-OREOVERREDUCING PRELOAD AND AFTERLOAD WITHOUTINCREASING HEART RATE IS CONSISTENT WITHDECREASEDMYOCARDIALOXYGENCONSUMPTIONANDADECREASE INVENTRICULAR STRESS

A STIMULUSPRESUMED TODRIVE THENEUROHORMONALACTIVATIONOF!$(&,ASTLYTOLERANCETOTHESEEFFECTSDOESNOTOCCURANDTHESECHANGESINHEMODYNAMICSAREPRESENTANDPERSISTENTTHROUGHOUTTHEADMINISTRATIONOFNESIRITIDE

4ODATENESIRITIDEISTHEONLYNATRIURETICPEPTIDEAVAILABLEINTHE53FOR)6THERAPY#OLUCCIETALINTHE%FlCACY4RIALSHOWED THATNESIRITIDECAUSESADOSERELATED DECREASE IN 0#70 SYSTEMIC VASCULARRESISTANCEMEANRIGHTARTERIALPRESSURE DYSPNEA FATIGUE A SIGNIlCANT INCREASEINCARDIACINDEXANDANIMPROVE

MENTINGLOBALSTATUS4HEMOSTCOMMONSIDEEFFECTWASDOSERELATEDHYPOTENSION4HE #OMPARATIVE 4RIAL EVALUATED NESIRITIDE VERSUSMANYOTHER CARDIOVASCULARAGENTS INCLUDING DOBUTAMINEMILRINONENITROGLYCERIN DOPAMINE AND AMRINONE'LOBAL CLINICAL STATUS FATIGUE AND DYSPNEAIMPROVEDINALLGROUPSWITHNOSIGNIlCANTDIFFERENCESBETWEENNESIRITIDEANDSTANDARDTHERAPY4HEMOSTCOMMONSIDEEFFECTSWEREBRADYCARDIAANDDOSERELATEDHYPOTENSION

)N "URGER ET AL CONDUCTED THE02%#%$%.4 STUDY )TS PRIMARY OBJECTIVE WAS TO COMPARE HEART RATE AND ARRHYTHMIAS WITH TWO DOSES OF NESIRITIDEORGKGMINTODOBUTAMINE4HEY CONCLUDED THAT ALTHOUGH INOTROPIC(&THERAPIESINCLUDINGDOBUTAMINEANDMILRINONEAREASSOCIATEDWITHFAVORABLEHEMODYNAMIC AND SYMPTOMATIC EFFECTSTHEY CAUSE ARRHYTHMIAS AND TACHYCARDIAWHICHMAY INCREASEMYOCARDIAL OXYGENDEMAND ISCHEMIA AND MORTALITY 4HEYDEMONSTRATED FEWER ARRHYTHMIAS ANDNOHEART RATE INCREASE WITH NESIRITIDE &URTHERMORE THE RATES OF DAY READMISSIONANDMONTHMORTALITYWEREHIGHERWITHDOBUTAMINE4HEAUTHORSCONCLUDEDTHAT NESIRITIDE IS SAFER THAN DOBUTAMINEFORSHORTTERM!$(&MANAGEMENT

4HE6-!# TRIALWAS A SAFETY AND EFlCACY STUDY OF INTRAVENOUS NESIRITIDEVERSUS INTRAVENOUS NITROGLYCERIN OR PLACEBOIN!$(&PATIENTSWITHDYSPNEAAT REST 3WAN 'ANZ CATHETERIZATION WASPERFORMEDINROUGHLYHALFAT THEPHYSICIANSCHOICE0ATIENTSWERERANDOMIZEDINTOFOURBLINDEDGROUPSEACHRECEIVINGSTANDARDTHERAPYANDlXEDDOSENESIRITIDE TITRATABLE NESIRITIDE TITRATABLE NITRO


} *]i

vviì]V>

iii>

i>>`

>V>iì`Vi`

w}ii]

ìVi>i`>

>V>i>Vi]

ii`Vi>

iii]

>ì`V

iV*

}i6>`>i>>}iivVi6>\*>i`>V>>i`}iiiV>}ii{

sssss

sSSS

SS

S

P%/ KU KU KU

P

0HDQ2EVHUYHGYDOXHPP+J

P%/ KU KU KUP

0HDQ&KDQJHPP+J

S s

sssss

s

SSS

SS

S

SYVSODFHER

SYV17*

3ODFHER 1LWURJO\FHULQ 1HVLULWLGH

YIELDANINTUITIVERATIONALEANDAREASONABLEEVIDENCEBASED APPROACH FOR!$(& ASSESSMENT AND MANAGEMENT/NEOFTHEMOSTVALUABLElNDINGSISTHATBEGINNINGVASOACTIVETHERAPYINTHE%$ISASSOCIATEDWITHADAYREDUCTIONINHOSPITALLENGTHOFSTAYCOMPAREDTO THERAPIES NOT INITIATED UNTIL AFTER ADMISSION 4HISSUGGESTSTHATTHECHOICEOFTHERAPYINTHE%$MAYCRITICALLYIMPACTTHECOURSEOFTHEPATIENT

).4%'2!4).'".0,%6%,3).4/!2!4)/.!,53%/&.%3)2)4)$%7HILE".0ISAPPROVEDBYTHE&$!FOR(&DIAGNOSISITSUSEFULNESSTOMONITORTREATMENTISSTILLUNDERSTUDY(OWEVERSOMESUGGESTIONSCANBEMADE7EBELIEVETHATONECANSTRATIFYPATIENTSTOTHEHIGHRISKCATEGORYINPARTBYUSING".0LEVELS&ONOROWRECENTLYANALYZEDTHE!$(%2%DATABASEANDFOUNDTHATHIGH"5.LEVELSPROVIDEAPOORPROGNOSISFORPATIENTSIN!$(&4HUS

/6"6 ,"" * / "-- /,/ /"\-1,9"/ *" - -1-* ,*",/

GLYCERIN OR PLACEBO .ESIRITIDE HAD A FASTER ONSETAND GREATER REDUCTION IN 0#70 THAN NITROGLYCERIN4HEIMPROVEMENTINCLINICALSTATUSANDDYSPNEAWASSIMILAR INBOTHGROUPS }i4HEYCONCLUDEDTHATWHENADDEDTOSTANDARDCARENESIRITIDEIMPROVESHEMODYNAMIC FUNCTIONMOREEFFECTIVELY THAN)6NITROGLYCERINORPLACEBO

)NANOTHEREVALUATIONARISKADJUSTEDCOMPARISONOFOUTCOMES FROM THE!$(%2% REGISTRY OFMORE THAN!$(&PATIENTSFOUNDIMPROVEDSURVIVALWITHVASODILATORSCOMPAREDTOINOTROPES7HENCOMPARINGVASODILATORSTHEREARESIMILAROUTCOMESBETWEENNESIRITIDEANDNITROGLYCERIN

4HE CURRENT APPROVEDUSE OF NESIRITIDE IS FOR!$(&!LTHOUGHGUIDELINESTATEMENTSARELACKINGTHETOTALITYOFDIAGNOSTICANDTHERAPEUTICDATAREGARDINGNESIRITIDE

THECOMBINATIONOFHIGH".0ANDPOORRENALFUNCTIONIDENTIlESHIGHRISKPATIENTS}i{

)FPATIENTSAREADMITTEDWITH".0LEVELSPGM,AND"5.LEVELSARELOWERRISKONECANOFTENSTARTTREATMENTWITHPARENTERALDIURETICS3UBSEQUENTLYTHEYCANBERECLASSIlEDINTOLOWORHIGHRISKGROUPSBASED ON THEIR RESPONSE OVER THE NEXT n HOURS4HOSEWITHANADEQUATEDIURESISA FALL IN".0ANDNODETERIORATIONINRENALFUNCTIONMAYBECANDIDATESFOR CONTINUED DIURETICSVASODILATORS UNTIL EUVOLEMIAIS REACHED(OPEFULLY THISWILL LEAD TO A".0 LEVELPGM,INTHESEPATIENTS)NONESTUDYPATIENTSWHOSEDISCHARGE".0LEVELSWEREPGM,HADAREASONABLELIKELIHOODOFNOTBEINGREADMITTEDWITHINTHEFOLLOWINGDAYS)FTHE".0LEVELWASPGM, THE VOLUME STATUS REQUIRED REEVALUATION )FTHEPATIENT ISNOTYETEUVOLEMICNESIRITIDEMIGHTBECONSIDEREDFORHOURS

)FPATIENTSAFTER RECEIVINGnHOURSOF INTRAVENOUSDIURETICSHAVEANINADEQUATEDIURESISNOCHANGEORANINCREASE IN".0ANDWORSENINGRENAL FUNCTION THEYSHOULDBECONSIDEREDATHIGHRISK)FTHEIRSYSTOLIC"0ISATLEASTMM(GTHEYCANBEGIVENnDAYSOF

NESIRITIDEWITHIVDIURETICS".0CANTHENBECHECKEDHOURSAFTERCESSATIONOFNESIRITIDEANDORALVASODILATORSANDDIURETICSCANBEUSEDUNTILEUVOLEMIAISACHIEVED

0ATIENTSWITHSYSTOLIC"0SMM(GOFTENNEEDVASOPRESSORSANDORINOTROPESSOMETIMESUNDER3WAN'ANZ GUIDANCE )N OUR EXPERIENCE AT THE #LEVELAND#LINICIFTHESEINDIVIDUALSSHOWIMPROVEMENTIN"0ANDSYMPTOMSWEWILL THEN TRANSITION THEIR THERAPYTO NESIRITIDE )F THERE IS NO IMPROVEMENT ON INOTROPESORPRESSORSFURTHERINVASIVESTRATEGIESSHOULDBECONSIDERED&INALLYITISCONCEIVABLETHATINPATIENTSWHOAREADMITTEDWITHVERYHIGH".0LEVELSORHAVEIMPAIRED RENAL FUNCTION NESIRITIDEMIGHT BE STARTEDIMMEDIATELY

-1,9)NSUMMARYTHE".0#ONSENSUS0ANELOFHASPROVIDEDCONSENSUSAPPROACHESFORTHEUSEOF".0FORTHEDIAGNOSISANDTREATMENTOF(&)DEALLYTHEUSEOFTHESERECOMMENDATIONSWILLIMPROVETHECAREOFYOURPATIENTS


,#',)*+',#'!/#,"1+)'

"1+#%0',#('"+,0*1%.%

)!& )!&)!&

%#'#%+-+)##('( (*)+,"#+,(*1(

)*(%

.*1-')*(% .*1)*(%

*,&',(),#('+(%'&&%$(%

"!&%!&%'#( "!%+"!&'"!"%"%"%%! "+! !&''+%'!! % !

*,&',(),#('+'('*#"!&%#("!%+ "&

&' #!( "!&&

*,&',(),#('+ (*/#,"(*+"($

(%'&!"'%"#&)&"'"%&!"%!&%''"""*

*,&',(),#('+ (*/#,"(%'(&!&%'+*'%"!!+&&

!#( "!%+"!&'"!"!&%!)&"'"%&+#%'!&)"!&%!!"'%"#&"%#""%#%(&"!

*,&',(),#('+*#"!&%('"%"!%+&+!%" &

}i{ *i}

,,

- 3ILVER7-AISEL!9ANCY#7-C#ULLOUGH0!"URNETT*#

&RANCIS'3-EHRA-20EACOCK7&&ONOROW''IBLER"-ORROW$!(OLLANDER*".0#ONSENSUS0ANEL!#LINICAL!PPROACHFORTHE$IAGNOSTIC0ROGNOSTIC3CREENING4REATMENT-ONITORINGAND4HERAPEUTIC2OLESOF.ATRIURETIC0EPTIDESIN#ARDIOVASCULAR$ISEASES#(&3UPPLn

#LERICO!)ERVASI'-ARIANI'#LINICALRELEVANCEOFTHEMEASUREMENTOFCARDIACNATRIURETICPEPTIDEHORMONESINHUMANS(ORM-ETAB2ESn

-AISEL!"TYPENATRIURETICPEPTIDELEVELSAPOTENTIALNOVELhWHITECOUNTvFORCONGESTIVEHEARTFAILURE*#ARD&AILn

"OOMAMA&6ANDER-EIRACKER!(0LASMA!AND"TYPENATRIURETICPEPTIDESPHYSIOLOGYMETHODOLOGYANDCLINICALUSE#ARDIOVASC2ESn

-AIR*(AMMERER,ERCHER!0UCHENDORF"4HEIMPACTOFCARDIACNATRIURETICPEPTIDEDETERMINATIONONTHEDIAGNOSISANDMANAGEMENTOFHEARTFAILURE#LIN#HEM,AB-EDn

,UCHNER!3TEVENS4,"ORGESON$$ETAL$IFFERENTIALATRIALANDVENTRICULAREXPRESSIONOFMYOCARDIAL".0DURINGEVOLUTIONOFHEARTFAILURE!M*0HYSIOL(n(

3TEIN",EVIN2.ATRIURETICPEPTIDESPHYSIOLOGYTHERAPEUTICPOTENTIALANDRISKSTRATIlCATIONINISCHEMICHEARTDISEASE!M(EART*n

7EIDMANN0(ASLER,'NADINGER-0ETAL"LOODLEVELSANDRENALEFFECTSOFATRIALNATRIURETICPEPTIDEINNORMALMAN*#LIN)NVESTn

#HARLES#*%SPINER%!2ICHARDS!-#ARDIOVASCULARACTIONSOF!.&CONTRIBUTIONSOFRENALNEUROHUMORALANDHEMODYNAMICFACTORSINSHEEP!M*0HYSIOL2n2

(UNT0*%SPINER%!.ICHOLLS-'ETAL$IFFERINGBIOLOGICALEFFECTSOFEQUIMOLARATRIALANDBRAINNATRIURETICPEPTIDEINFUSIONSINNORMALMAN*#LIN%NDOCRINOL-ETABn

-UKOYAMA-.AKAO+(OSODA+ETAL"RAINNATRIURETICPEPTIDEASANOVELCARDIACHORMONEINHUMANS%VIDENCEFORANEXQUISITEDUALNATRIURETICPEPTIDESYSTEMATRIALNATRIURETICPEPTIDEANDBRAINNATRIURETICPEPTIDE*#LIN)NVESTn

$AVIDSON.#3TRUTHERS!$"RAINNATRIURETICPEPTIDE*(YPERTENSIONn

3AGNELLA'!-EASUREMENTANDIMPORTANCEOFPLASMABRAINNATRIURETICPEPTIDEANDRELATEDPEPTIDES!NN#LIN"IOCHEMn

#LERICO!)ERVASI'-ARIANI'#LINICALRELEVANCEOFTHEMEASUREMENTOFCARDIACNATRIURETICPEPTIDEHORMONESINHUMANS(ORM-ETAB2ESn

7IECZOREK3*7U!(#HRISTENSON2ETAL!RAPID"TYPENATRIURETICPEPTIDEASSAYACCURATELYDIAGNOSESLEFTVENTRICULARDYSFUNCTIONANDHEARTFAILUREAMULTICENTEREVALUATION!M(EART*n

2EDlELD--2ODEHEFFER2**ACOBSEN3*ETAL0LASMABRAINNATRIURETICPEPTIDECONCENTRATIONIMPACTOFAGEANDGENDER*!M#OLL#ARDIOLn

&RIESINGER'#&RANCIS*0ROMISESANDPERILSOFMANAGEDCAREFOROLDERPATIENTSWITHCARDIACDISEASE#ARDIOL#LINn

".0TESTFORRAPIDQUANTIlCATIONOF"TYPENATRIURETICPEPTIDE;PACKAGEINSERT=3AN$IEGO#ALIF"IOSITE$IAGNOSTICS

4HE3/,6$)NVESTIGATORS%FFECTOFENALAPRILONMORTALITYANDTHEDEVELOPMENTOFHEARTFAILUREINASYMPTOMATICPATIENTSWITHREDUCEDVENTRICULAREJECTIONFRACTIONSANDCONGESTIVEHEARTFAILURE.%NGL*-EDn

3TEVENSON,74HELIMITEDAVAILABILITYOFPHYSICALSIGNSFORESTIMATINGHEMODYNAMICSINCHRONICHEARTFAILURE*!-!n

(YPERTENSIONANDGENERALPOPULATIONRESEARCH(YPERTENSIONPT))n))

7UERZ2#-EADOR3!%FFECTSOFPREHOSPITALMEDICATIONSONMORTALITYANDLENGTHOFSTAYIN(&!NN%MERG-EDn

$EVERAUX2",IEBSON02(ORAN-*2ECOMMENDATIONSCONCERNINGUSEOFECHOCARDIOGRAPHYINHYPERTENSIONANDGENERALPOPULATIONRESEARCH(YPERTENSIONPT))n))

$AVIE!0&RANCIS#-,OVE-0ETAL6ALUEOFTHEELECTROCARDIOGRAMINIDENTIFYINGHEARTFAILUREDUETOLEFTVENTRICULARSYSTOLICDYSFUNCTION"-*

-AISEL!+RISHNASWAMY0.OWAK2-ETAL2APIDMEASUREMENTOF"TYPENATRIURETICPEPTIDEINTHEEMERGENCYDIAGNOSISOFHEARTFAILURE.%NGL*-EDn

-UELLER#3CHOLER!,AULE+ILIAN+ETAL5SEOF"TYPENATRIURETICPEPTIDEINTHEEVALUATIONANDMANAGEMENTOFACUTEDYSPNEA.%NGL*-EDn

7OLDE-4ULEVSKI))-ULDER*7ETAL"RAINNATRIURETICPEPTIDEASAPREDICTOROFADVERSEOUTCOMEINPATIENTSWITHPULMONARYEMBOLISM#IRCULATION

,EUCHTE(((OLZAPFEL-"AUMGARTNER2!ETAL#LINICALSIGNIlCANCEOFBRAINNATRIURETICPEPTIDEINPRIMARYPULMONARYHYPERTENSION*!##n

,UBIEN%$E-ARIA!+RISHNASWAMY0ETAL5TILITYOF"NATRIURETIC0EPTIDE".0INDIAGNOSINGDIASTOLICDYSFUNCTION#IRCULATIONn

/6"6 ,"" * / "-- /,/ /"\-1,9"/ *" - -1-* ,*",/

+RISHNASWAMY0,UBIEN%#LOPTON0ETAL5TILITYOF"NATRIURETICPEPTIDE".0INELUCIDATINGLEFTVENTRICULARDYSFUNCTIONSYSTOLICANDDIASTOLICINPATIENTSWITHANDWITHOUTSYMPTOMSOFCONGESTIVEHEARTFAILUREATAVETERANSHOSPITAL!M*-EDn

-AISEL!3-C#ORD*-.OWAK2-ETAL"EDSIDE"TYPENATRIURETICPEPTIDEINTHEEMERGENCYDIAGNOSISOFHEARTFAILUREWITHREDUCEDORPRESERVEDEJECTIONFRACTIONRESULTSFROMTHE"REATHING.OT0ROPERLY".0MULTINATIONALSTUDY*!M#OLL#ARDIOLn

(UBERT("&EINLEIB--C.AMARA0-AND#ASTELLI70/BESITYASANINDEPENDENTRISKFACTORFORCARDIOVASCULARDISEASEAYEARFOLLOWUPOFPARTICIPANTSINTHE&RAMINGHAM(EART3TUDY#IRCULATION-%$,).%

%CKEL2("AROUCH77%RSHOW!'2EPORTOFTHE.ATIONAL(EART,UNGAND"LOOD)NSTITUTE.ATIONAL)NSTITUTEOF$IABETESAND$IGESTIVEAND+IDNEY$ISEASES7ORKING'ROUPONTHE0ATHOPHYSIOLOGYOF/BESITY!SSOCIATED#ARDIOVASCULAR$ISEASE#IRCULATIONn

!LPERT-!,AMBERT#2AND0ANAYIOTOU(ETAL2ELATIONOFDURATIONOFMORBIDOBESITYTOLEFTVENTRICULARMASSSYSTOLICFUNCTIONANDDIASTOLIClLLINGANDEFFECTOFWEIGHTLOSS!M*#ARDIOL-%$,).%

+ENCHAIAH3%VANS*#AND,EVY$ETAL/BESITYANDTHERISKOFHEARTFAILURE.%NGL*-ED

3ARZANI2$ESSI&ULGHERI00ACI6-%SPINOSA%AND2APPELLI!*%XPRESSIONOFNATRIURETICPEPTIDERECEPTORSINHUMANADIPOSEANDOTHERTISSUES*%NDOCRINOL)NVEST-%$,).%

3ENGENES#"ERLAN-$E'LISEZINSKI),AFONTAN-AND'ALITZKY*.ATRIURETICPEPTIDESANEWLIPOLYTICPATHWAYINHUMANADIPOCYTES&!3%"*-%$,).%

-EHRA-25BER0!0ARK-ETAL/BESITYANDSUPPRESSED"TYPENATRIURETICPEPTIDELEVELSINHEARTFAILURE*!##n

+IKUTA+9ASUE(9OSHIMURA-ETAL)NCREASEDPLASMALEVELSOF"TYPENATRIURETICPEPTIDEINPATIENTSWITHUNSTABLEANGINA!M(EART*n

4ALWAR33QUIRE)"$OWNIE0&ETAL0LASMA.TERMINALPROBRAINNATRIURETICPEPTIDEANDCARDIOTROPHINARERAISEDINUNSTABLEANGINA(EARTn

DE,EMOS*!-ORROW$!"ENTLEY*(ETAL4HEPROGNOSTICVALUEOF"TYPENATRIURETICPEPTIDEINPATIENTSWITHACUTECORONARYSYNDROMES.%NGL*-EDn

(ARRISON!-ORRISON,++RISHNASWAMY0ETAL"TYPENATRIURETICPEPTIDE".0PREDICTSFUTURECARDIACEVENTSINPATIENTSPRESENTINGTOTHEEMERGENCYDEPARTMENTWITHDYSPNEA!NN%MERG-EDn

#OLUCCI7%LKAYAM5(ORTON$ETAL)NTRAVENOUSNESIRITIDEANATRIURETICPEPTIDEINTHETREATMENTOFDECOMPENSATEDCONGESTIVEHEARTFAILURE.%NGL*-EDn

3ILVER-!(ORTON$0'HALI*+ETAL%FFECTOFNESIRITIDEVERSUSDOBUTAMINEONSHORTTERMOUTCOMESINTHETREATMENTOFPATIENTSWITHACUTELYDECOMPENSATEDHEARTFAILURE*!M#OLL#ARDIOLn

"URGER!(ORTON$,E*EMTEL4%FFECTSOFNESIRITIDE"TYPENATRIURETICPEPTIDEANDDOBUTAMINEONVENTRICULARARRHYTHMIASINTHETREATMENTOFPATIENTSWITHACUTELYDECOMPENSATEDCONGESTIVEHEARTFAILURETHE02%#%$%.4STUDY!M(EART*n

0UBLICATION#OMMITTEEFORTHE6-!#)NVESTIGATORS6ASODILATORSINTHE-ANAGEMENTOF!CUTE(&)NTRAVENOUSNESIRITIDEVSNITROGLYCERINFORTREATMENTOFDECOMPENSATEDCONGESTIVEHEARTFAILUREARANDOMIZEDCONTROLLEDTRIAL*!-!n

!$(%2%3CIENTIlC!DVISORY#OMMITTEE4HE!CUTE$ECOMPENSATED(EART&AILURE.ATIONAL2EGISTRY!$(%2%OPPORTUNITIESTOIMPROVECAREOFPATIENTSHOSPITALIZEDWITHACUTEDECOMPENSATEDHEARTFAILURE2EV#ARDIOVASC-EDSUPPL3n3

-EHRA-25BER0!0OTLURI36ENTURA(/3COTT2,0ARK-(5SEFULNESSOFANELEVATEDBTYPENATRIURETICPEPTIDETOPREDICTALLOGRAFT

#HENG6,+RISHNASWAMY0+AZANEGRA2ETAL!RAPIDBEDSIDETESTFOR"TYPENATRIURETICPEPTIDEPREDICTSTREATMENTOUTCOMESINPATIENTSADMITTEDWITHDECOMPENSATEDHEARTFAILURE*!M#OLL#ARDIOLn



/iVi

iVi>i`

i>>i >>

,i},

>ìii`

ì>>}i]>>

`>>L>iìVL}i

VV>V>>ViV]

V>>VVi>`

i>i>i]

>`Viv

>i>i`

,"1 -,"/, /" ,-/,9

7ILLIAM4!BRAHAM-$#HIEF$IVISIONOF#ARDIOVASCULAR-EDICINE

4HE/HIO3TATE5NIVERSITY#OLLEGEOF-EDICINE#OLUMBUS/(

/,"1/" !CUTEDECOMPENSATEDHEARTFAILURE!$(&REPRESENTSAMAJORPUBLICHEALTHPROBLEM)NTHE5NITED3TATESTHEREAREAPPROXIMATELYMILLIONHOSPITALIZATIONSANNUALLYWITHAPRIMARYDISCHARGEDIAGNOSISOF!$(&.EARLYTWICEASMANYHOSPITALIZATIONSAREASSOCIATEDWITHHEARTFAILUREASASECONDARYDIAGNOSIS4HESENUMBERSAREEXPECTEDTOINCREASEOVERTHENEXTTWODECADES(EARTFAILURETAKESAPARTICULARLYHIGHTOLLONTHEELDERLY3INCETHEEARLYS!$(&HASBEENTHELEADINGCAUSEOFHOSPITALIZATIONINPERSONSOVERTHEAGEOFYEARS2EPORTEDDEATHRATESAPPEAREXCESSIVEBOTHDURINGANDAFTERHOSPITALIZATIONANDHIGHREADMISSIONRATESSUGGESTTHATINPATIENTCAREDOESNOTRESULTINEFFECTIVELONGTERMMANAGEMENT4HEENORMOUSDIRECTCOSTSASSOCIATEDWITHTREATINGTHEMILLION!MERICANSWITHCHRONICHEARTFAILUREAREMOSTLYATTRIBUTABLETOTHEINPATIENTMANAGEMENTOFEPISODESOFDECOMPENSATION)THASBEENPROPOSEDTHATTHESEDISMALSTATISTICSEXISTINPARTDUETOAPOORUNDERSTANDINGOFTHECHARACTERISTICSOFPATIENTSADMITTEDWITH!$(&ANDHOWTOTREATTHEM)NTHISREGARDMOSTINFORMATIONABOUT!$(&ISDERIVEDFROMCLINICALTRIALSTHATARESMALLHUNDREDSOFPATIENTSANDPOORLYREPRESENTATIVEOFPATIENTSHOSPITALIZEDFOR!$(&DUETOTHEMANYINCLUSIONANDEXCLUSIONOFSUCHTRIALS

!FEWREGISTRIESHAVEBEENDEVELOPEDTOEVALUATECHRONICHEART FAILURE IN THEOUTPATIENTCOMMUNITYSETTING4HE!CUTE$ECOMPENSATED(EART&AILURE.ATIONAL2EGISTRY!$(%2%WASDEVELOPEDTOPROVIDEALARGENATIONALDATABASEDESCRIBINGTHECLINICALCHARACTERISTICS PHYSICIAN PRACTICE AND TREATMENT PATTERNS AND OUTCOMES OF PATIENTSHOSPITALIZEDWITH!$(&

"/6-\ iVLiii`>`Vivi,i} iVLiw`}vi,i}V>Lii`ìV>ìV>i

v>i

-ETHODOLOGYOF!$(%2%!$(%2% IS A LARGE MULTICENTER REGISTRY DESIGNED TO AMASS A LARGE CLINICALDATABASE ON THE CLINICAL CHARACTERISTICSMANAGEMENT AND OUTCOMES OF PATIENTSHOSPITALIZEDFOR!$(&ACROSSTHE5NITED

3TATES$ATAARECOLLECTEDONTHEEPISODEOF HOSPITALIZATION BEGINNING WITH THEPOINTOFINITIALCAREANDENDINGWITHTHEPATIENTS DISCHARGE TRANSFER OUT OF THEHOSPITALOR INHOSPITALDEATH!$(%2%IS SPONSORED BY 3CIOS )NC &REMONT


#ALIFORNIA4HESPECIlCOBJECTIVESOF!$(%2%ARETODESCRIBETHEDEMOGRAPHICANDCLINICALCHARACTERISTICSOFPATIENTSWHOAREHOSPITALIZEDWITH!$(&INCLUDINGSPECIlCSUBGROUPSOFINTERESTTOCHARACTERIZETHEINITIALEMERGENCYDEPARTMENTEVALUATIONAND SUBSEQUENT INPATIENT MANAGEMENT OF PATIENTSHOSPITALIZEDWITH!$(&TOIDENTIFYPATIENTCHARACTERISTICSANDMEDICALCAREPRACTICESASSOCIATEDWITHIMPROVED HEALTH OUTCOMES IN PATIENTS HOSPITALIZEDWITH!$(& TO CHARACTERIZE TRENDS OVER TIME INTHEMANAGEMENTOF!$(&ANDTOASSISTHOSPITALSIN EVALUATING AND IMPROVING QUALITY OF CARE FOR PATIENTSHOSPITALIZEDWITHHEARTFAILURE!DDITIONALGOALSOF!$(%2%INCLUDEDEVELOPMENTOFPREDICTIVEMODELS FORMORTALITY COMPLICATIONS AND LENGTH OF HOSPITALSTAYANDTOLINKWITHDEIDENTIlEDDATAONLONGITUDINALTRENDSINTHECLINICALCAREANDOUTCOMESOFREGISTRYPATIENTS!GGREGATEDATAFROMTHE!$(%2%DATABASE IS ALSOUSED FOR THEOBSERVATIONAL STUDYOFTREATMENTEFFECTS

3ITESWERE SELECTED TO REPRESENT THE hREALWORLDvOF!$(&3ITES INCLUDEDBOTH ACADEMIC HOSPITALSANDNONACADEMICHOSPITALSHOSPITALSANDWEREGEOGRAPHICALLYDIVERSE INCLUDINGHOSPITALS IN THE.ORTHEASTERN5NITED3TATESHOSPITALSINTHE3OUTHHOSPITALSINTHE-IDWESTHOSPITALSINTHE7ESTANDHOSPITALSINTHE-ID!TLANTICREGION3OMEOFTHE LARGEST ACUTE CAREHOSPITALS IN THE5NITED3TATESAREPARTICIPATINGBUTSITESAREDIVERSEINSIZERANGINGFROMTOBEDS3ITESAREREIMBURSEDANOMINALFEEFOREACHCOMPLETEDCASEREPORTFORM

&ORTHEPURPOSEOFTHISREGISTRY!$(&ISDElNEDASEITHERNEWONSETHEART FAILUREORDECOMPENSATIONOFCHRONICESTABLISHEDHEARTFAILUREWITHSYMPTOMSSUFlCIENT TOWARRANT HOSPITALIZATION 0ATIENTS ARE IDENTIlED FOR INCLUSION IN THE REGISTRY FROM ADMISSIONSGIVENADISCHARGEDIAGNOSISOFHEARTFAILUREBASEDON)NTERNATIONAL#LASSIlCATIONOF$ISEASES.INTH2EVI

SION)#$CODING%LIGIBILITYISNOTCONTINGENTONTHEUSEOFANYPARTICULARTHERAPEUTICAGENTORREGIMEN0ATIENTSMAYBEMALEORFEMALEANDMUSTBEATLEASTYEARSOLD AT THE TIMEOFHOSPITAL ADMISSION4HEREGISTRY ISACCUMULATINGDATAON INDIVIDUALHOSPITALIZATIONSNOTINDIVIDUALPATIENTSANDITISPOSSIBLETHATSOME PATIENTSMAY BE ENROLLED IN THE REGISTRYMORETHANONCE4HEGOALOFTHEREGISTRYISTOENROLLAREPRESENTATIVEPATIENTSAMPLE3ITESAREENCOURAGEDTOENROLLADMISSIONSMEETINGENTRYCRITERIAASCONSECUTIVELYASPOSSIBLE(OSPITALSWITHMORETHANELIGIBLEPATIENTSINAMONTHAREALLOWEDTOENROLLARANDOMSAMPLEOFTHESECONSECUTIVEADMISSIONSUSINGA*OINT#OMMISSION FOR !CCREDITATION OF (EALTHCARE /RGANIZATIONS*#!(/nAPPROVEDSAMPLINGMETHOD3PECIlCATIONS-ANUALFOR.ATIONAL)MPLEMENTATIONOF(OSPITAL#ORE-EASURES*#!(/SECTION

$ATAARECOLLECTEDBYCHARTREVIEWANDENTEREDUSINGA WEBBASED ELECTRONIC DATA CAPTURE %$# SYSTEMDESIGNEDBY0HASE&ORWARD7ALTHAM-ASSANDLICENSED BY THE STUDY CONTRACT RESEARCH ORGANIZATION0HARMA,INK&()2ESEARCH4RIANGLE.#$ATAARERECORDED CONCERNING DEMOGRAPHICS MEDICAL HISTORY NONINTRAVENOUS AND INTRAVENOUS CARDIOVASCULAR MEDICATIONS INITIAL EVALUATION AT SITE HOSPITALCHRONICINFUSIONTHERAPYHOSPITALCOURSEDISPOSITIONANDPROCEDURES )NFORMATION RELATED TO FOUR SPECIlCASPECTSOFTHE*#!(/QUALITYIMPROVEMENTINITIATIVEFORHEARTFAILUREAREALSOCAPTUREDPATIENTINSTRUCTIONONDIETWEIGHTANDMEDICATIONMANAGEMENTATDISCHARGEASSESSMENTOF LEFTVENTRICULARSYSTOLICFUNCTIONDOCUMENTEDOR SCHEDULED ANGIOTENSINCONVERTINGENZYME!#%INHIBITORUSEATDISCHARGEIN PATIENTS CONSIDERED CANDIDATES FOR THIS THERAPYBASEDONACCEPTEDCLINICALCRITERIAANDCOUNSELINGONSMOKINGCESSATIONINCURRENTSMOKERS(UMANSUBJECTS CONSIDERATIONS PATIENT CONlDENTIALITY SITEMONITORINGANDOTHERSPECIlCMETHODOLOGICALISSUESHAVEBEENPREVIOUSLYOUTLINEDINDETAILELSEWHERE

,"1 -,"/, /" ,-/,9

)NSIGHTSFROM!$(%2%&ROM/CTOBERTHROUGH$ECEMBERHEART FAILUREDISCHARGESWERE ENROLLED IN!$(%2%4HEMEAN AGE OF PATIENTSWAS YEARS AND WEREWOMEN-OSTPATIENTSWEREWHITEORBLACK ANDWERE COVERED BY-EDICARE OR-EDICAID3EVENTYSIXPERCENTOFPATIENTSENROLLEDHADAPRIORHISTORYOFHEARTFAILUREANDONETHIRDHADAHISTORYOFADMISSIONFOR!$(&WITHINTHEPRIORMONTHS!HISTORYOFHYPERTENSIONWASCOMMONASWASCORONARY ARTERY DISEASE AND DIABETES /THER IMPORTANT OR COMMON COMORBID CONDITIONSINCLUDEDHISTORYOF ATRIALlBRILLATION CHRONICOBSTRUCTIVE PULMONARY DISEASE OR ASTHMA ANDCHRONICRENALINSUFlCIENCY-OSTPATIENTSPRESENTEDWITHDYSPNEA2ALESANDPERIPHERALEDEMAWERE PRESENT IN AND OF THE CASESRESPECTIVELY/F PATIENTSWITH DOCUMENTED LEFT VENTRICULAREJECTIONFRACTIONPRIORTOADMISSIONHADPRESERVEDORONLYMILDLYDEPRESSEDSYSTOLICFUNCTION4HECHARACTERISTICSOFPATIENTSENROLLEDIN!$(%2%AREVERYDIFFERENTFROMTHOSEOFPATIENTSINCLUDEDINCLINICALTRIALSQ/>LiR

4HEMEDIANLENGTHOFSTAYFORALLHOSPITALIZ

dx y tx de icc

Documents